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ABSTRACT 
Although many different materials, techniques and methods, including artificial or 
engineered bone substitutes, have been used to repair various bone defects, the 
restoration of critical-sized bone defects caused by trauma, surgery or congenital 
malformation is still a great challenge to orthopedic surgeons. One important fact that 
has been neglected in the pursuit of resolutions for large bone defect healing is that 
most physiological bone defect healing needs the periosteum and stripping off the 
periosteum may result in non-union or non-healed bone defects. Periosteum plays 
very important roles not only in bone development but also in bone defect healing. 
The purpose of this project was to construct a functional periosteum in vitro using a 
single stem cell source and then test its ability to aid the repair of critical-sized bone 
defect in animal models. This project was designed with three separate but 
closely-linked parts which in the end led to four independent papers.  
 
The first part of this study investigated the structural and cellular features in periostea 
from diaphyseal and metaphyseal bone surfaces in rats of different ages or with 
osteoporosis. Histological and immunohistological methods were used in this part of 
the study. Results revealed that the structure and cell populations in periosteum are 
both age-related and site-specific. The diaphyseal periosteum showed age-related 
degeneration, whereas the metaphyseal periosteum is more destructive in older aged 
rats. The periosteum from osteoporotic bones differs from normal bones both in terms 
of structure and cell populations. This is especially evident in the cambial layer of the 
metaphyseal area. Bone resorption appears to be more active in the periosteum from 
osteoporotic bones, whereas bone formation activity is comparable between the 
osteoporotic and normal bone. The dysregulation of bone resorption and formation in 
the periosteum may also be the effect of the interaction between various neural 
pathways and the cell populations residing within it. 
 
One of the most important aspects in periosteum engineering is how to introduce new 
blood vessels into the engineered periosteum to help form vascularized bone tissues in 
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bone defect areas. The second part of this study was designed to investigate the 
possibility of differentiating bone marrow stromal cells (BMSCs) into the endothelial 
cells and using them to construct vascularized periosteum. The endothelial cell 
differentiation of BMSCs was induced in pro-angiogenic media under both normoxia 
and CoCl2 (hypoxia-mimicking agent)-induced hypoxia conditions. The VEGF/PEDF 
expression pattern, endothelial cell specific marker expression, in vitro and in vivo 
vascularization ability of BMSCs cultured in different situations were assessed. 
Results revealed that BMSCs most likely cannot be differentiated into endothelial 
cells through the application of pro-angiogenic growth factors or by culturing under 
CoCl2-induced hypoxic conditions. However, they may be involved in angiogenesis 
as regulators under both normoxia and hypoxia conditions. Two major 
angiogenesis-related growth factors, VEGF (pro-angiogenic) and PEDF 
(anti-angiogenic) were found to have altered their expressions in accordance with the 
extracellular environment. BMSCs treated with the hypoxia-mimicking agent CoCl2 
expressed more VEGF and less PEDF and enhanced the vascularization of 
subcutaneous implants in vivo.   
 
Based on the findings of the second part, the CoCl2 pre-treated BMSCs were used to 
construct periosteum, and the in vivo vascularization and osteogenesis of the 
constructed periosteum were assessed in the third part of this project. The findings of 
the third part revealed that BMSCs pre-treated with CoCl2 could enhance both ectopic 
and orthotopic osteogenesis of BMSCs-derived osteoblasts and vascularization at the 
early osteogenic stage, and the endothelial cells (HUVECs), which were used as 
positive control, were only capable of promoting osteogenesis after four-weeks. The 
subcutaneous area of the mouse is most likely inappropriate for assessing new bone 
formation on collagen scaffolds. This study demonstrated the potential application of 
CoCl2 pre-treated BMSCs in the tissue engineering not only for periosteum but also 
bone or other vascularized tissues.   
 
In summary, the structure and cell populations in periosteum are age-related, 
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site-specific and closely linked with bone health status. BMSCs as a stem cell source 
for periosteum engineering are not endothelial cell progenitors but regulators, and 
CoCl2-treated BMSCs expressed more VEGF and less PEDF. These CoCl2-treated 
BMSCs enhanced both vascularization and osteogenesis in constructed periosteum 
transplanted in vivo.  
 
Key words: periosteum, osteoporosis, bone marrow, vascularization, osteogenesis, 
angiogenesis, differentiation, endothelial cell, tissue engineering, bone defect healing 
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CHAPTER 1 INTRODUCTION 
1.1  PREFACE 
Orthopedic surgeons have long held the aspiration to properly heal bone defects - 
caused by trauma, inflammation or tumors - and regain its normal function, despite 
the size of the defect.  To realize this ambition, innumerable studies have been 
conducted into autogeneic, allogeneic and even xenogeneic bone transplantation 
therapies [1].  However, insufficient donor tissue, coupled with concerns about donor 
site morbidity, has hindered autologous transplantation for large-scale applications.  
On the other hand, immunological repulsive reactions in the recipient against allo or 
xenogeneic bone grafts impose severe limitations on the clinical application of these 
approaches. Added to these considerations, additional operations to harvest bone 
substitute in allograft may further compromise the health of the patient.  
 
Advances in cell and molecular biology, especially in the knowledge of the 
underlying mechanisms of bone defect healing and tissue engineering techniques, 
have thrown a new light on the repair of various sized bone defects.  The main 
purpose of bone tissue engineering is to construct a substitute for bone defects, in 
vitro and in vivo, in order to restore defects and normal function.  Natural 
biomaterials (e.g. collagen, chitosan, hyaluronic acid, decalcified bone matrix, etc), 
synthetic polymers (e.g. PLA, PGA, PLLA, PDLA, PLGA) and bioceramics (e.g. HA, 
TCP, bioglass etc.) are most frequently used in bone tissue engineering [2].  These 
materials serve both as templates to restore the shape of bone defects and also as 
scaffolds to deliver therapeutic cells and/or various related growth factors[3-5].  The 
expectation is that the engineered bone substitutes can integrate with host bone tissues 
and thus restore the physiological structure and function of the defects. However, 
there remain obvious problems as to the practical application of bone tissue 
engineering technology.  The in vitro engineered bone substitute is usually an 
“ossified block” rather than “physiologically and anatomically restored bone defect 
substitute”.  How these “engineered ossified blocks” integrate with host bone tissues, 
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at the implant/host junction, is obviously different from natural bone fracture healing.  
The final mechanical strength at the implant/host junction needs to be carefully 
investigated and compared to that in natural bone fracture healing.  Another concern 
is the cell viability of large cell containing substitutes, since these are 3-dimensional 
and the diffusion distance of nutrients and oxygen for cell survival is in the order of 
150-200µm[6].  Even if the scaffold used to deliver cells could be designed with 
larger pore size and greater porosity to maximize the permeability of the materials, 
decreased mechanical strength of the scaffold would then become another problem in 
the in vivo application, especially at the load-bearing site. Consequently, critical-sized 
bone defects, requiring large 3D engineered substitutes in order to restore function, 
pose a great challenge in orthopedic surgery [7].  Many methods have been 
developed to increase the vascularization of bone implants such as combining 
angiogenic growth factors (e.g. VEGF and FGF) with the scaffold as well as gene 
transfection[8].  However, the results to date have been disappointing due to 
difficulties associated with the controlled release of growth factors, causing an 
unpredictable degree of vascularization and even oncogenesis.  
 
In terms of bone physiology the periosteum plays a determining role in bone 
formation and defect healing in addition to the involvement of other important factors.  
The periosteum is a highly vascularized tissue that contains osteogenic and 
chondrogenic progenitor cells as well as other related bioactive factors.  
Transplantation of autogenous or allogenous periosteum has been applied successfully 
in the repair of various sized bone defects, especially in large bone defects.  Bone 
healing induced by periosteum has natural advantages over the other methods 
mentioned above such as: healing with natural bone structure, optimal implant/host 
integrity, appropriate vascularization and minimal ectopic ossification through 
encasing of the defect site.  This therapeutic concept for bone defect restoration is 
“membrane-cell-based” rather than “bone-structure-based”. However, some major 
concerns in relation to this concept exist in the harvesting of periosteum, namely 
insufficient donor material, donor site morbidity and immunological concerns.  
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1.2  MAIN PURPOSES OF THIS STUDY 
The main purpose of this study is to construct a dual-layered periosteum in vitro, 
based on the natural structure and cell populations of the periosteum during active 
osteogenesis.  This engineered periosteum will contain osteogenic progenitors in the 
inner layer and blood vessel forming or recruiting cells in the outer layer. The 
induction of new bone formation by engineered periosteum will be tested in vivo. 
 
1.3  QUESTIONS TO BE ADDRESSED 
1. What are the structural and cellular features of periosteum? Are these features 
same or different at different sites on the bone surface? Does the age affect 
these features? Will these features change in osteoporosis? 
 
2. Could we use bone marrow mesenchymal stem cells (BMSCs) to construct a 
dual-layered periosteum in vitro? Could the BMSCs be differentiated into 
endothelial cells or could the BMSCs be used to help vascularization of the 
engineered periosteum and how? 
 
3. Could the engineered perioteum induce new bone formation and help restore 
large-sized bone defect in vivo? 
 
1.4  POSSIBLE OUTCOMES AND SIGNIFICANCE 
Based on earlier attempts to artificially engineer periosteum in vitro, the concept of 
“membrane-cell-based” engineering for bone defect restoration will be emphasized in 
this project.  More knowledge about the periosteum and cell-cell interactions within 
may be revealed through this project. This project is believed the first to construct a 
dual-layered periosteum tissue using a single stem cell source and test its osteogenic 
function in vivo.  Interactions between different cell populations in the periosteum 
can be investigated using the engineered periosteum as a model.  A possible 
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commercial outcome may arise should the artificially engineered periosteum be of a 
quality that it could to be manufactured and marketed as a medical product. 
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CHAPTER 2 OVERVIEW OF PROJECT DESIGN  
2.1  UNDERSTANDING THE STRUCTURE OF PERIOSTEUM  
 
2.1.1 PERIOSTEUM CHANGES DURING BONE DEVELOPMENT 
The femoral periostea of twelve female Lewis rats of various age groups were fixed 
and stained with hematoxylin and eosin. The thickness of cambial and fibrous layers 
of periostea at different periosteal sites (diaphyseal and metaphyseal) were measured 
and the number of cells in each layer counted.  Changes in the structure and cell 
number from different age groups and periosteal sites were analyzed. Subsequent 
immunohistochemical staining was performed using several specific antibodies to 
identify the cell populations in the periosteum in different age groups and periosteal 
sites. 
 
  2.1.2 PERIOSTEUM CHANGES IN NORMAL AND 
OSTEOPOROTIC RATS 
The femoral periostea of three normal and four osteoporotic Lewis rats were fixed and 
stained with hematoxylin and eosin.  The thickness of cambial and fibrous layers of 
periostea at different periosteal sites (diaphyseal and metaphyseal) were measured and 
the number of cells in each layer counted.  Changes in the structure and cell number 
between the two groups were analyzed. Subsequent immunohistochemical staining 
was performed using several specific antibodies to identify the cell populations in the 
periosteum from the two groups. 
 
2.2  ANGIOGENIC DIFFERENTIATION OF BMSCs 
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2.2.1 Angiogenic differentiation of BMSCs in normoxia 
BMSCs were cultured in complete DMEM (10% FBS, 1% Pen/Strep) until passage 2.  
The cells were then seeded into 6-well culture plates and cultured in media 
supplemented with 5% FBS and 20, 40 or 80ng/ml VEGF.  After 6-day culturing, the  
expression of relevant endothelial cell markers (vWF, VEGFR2, eNOS and CD31), 
pro- and anti-angiogenic growth factors (VEGF and PEDF) was determined by 
RT-qPCR, western blot, flow cytometry or immunohistochemistry staining and 
compared with undifferentiated BMSCs and human umbilical vein endothelial cells 
(HUVECs) as controls.  The ability to form vessel network structures on the matrigel 
of BMSCs cultured in different situations was assessed. 
 
2.2.2 Angiogenic differentiation of BMSCs in CoCl2-induced 
hypoxia 
BMSCs were cultured in complete DMEM (10% FBS, 1% Pen/Strep) until passage 2.  
The cells were then seeded into 6-well culture plates and cultured in media 
supplemented with 5% FBS, 100µM CoCl2 and/or 20ng/ml VEGF.  After 6-day 
culturing, the  expression of relevant endothelial cell markers (vWF, VEGFR2, 
eNOS and CD31), pro- and anti-angiogenic growth factors (VEGF and PEDF) was 
determined by RT-qPCR, western blot, flow cytometry or immunohistochemistry 
staining and compared with untreated BMSCs and human umbilical vein endothelial 
cells (HUVECs) as controls.  The ability to form vessel network structures on the 
matrigel of BMSCs cultured in different situations was assessed.  
 
2.2.3 In vivo angiogenesis of BMSCs cultured under different 
conditions 
The HUVECs, untreated BMSCs and the BMSCs treated with VEGF and/or 100µM 
CoCl2 were mixed with matrigel and injected into the subcutaneous area of three 
SCID mice. After 10 days, the implants were harvested, fixed and sliced. The density 
of blood vessels on each slice was analyzed and compared among groups. 
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2.3  PERIOSTEUM ENGINEERING AND ITS IN VIVO 
ASSESSMENT 
2.3.1 Periosteum engineering using BMSCs-derived osteoblasts 
(Bost) together with HUVECs or CoCl2-treated BMSCs 
BMSCs were seeded on to one side of a collagen membrane and cultured in 
osteogenic media for 2 weeks, and then undifferentiated BMSCs, HUVECs or 
CoCl2-treated BMSCs were seeded onto the other side of the membrane. The 
membrane without cells or seeded with only undifferentiated BMSCs or carrying Bost 
only was used as controls. The osteogenesis and vascularization of all these scaffolds 
were tested in vivo.  
 
2.3.2 In vivo test for subcutaneous osteogenesis and 
vascularisation   
4 SCID mice were used for this experiment.  On the dorsal area of each mouse, 6 
scaffolds from each group mentioned above were implanted under the skin. After 2 
weeks, the implants were harvested. Then the Micro-CT scanning analysis, 
histological and immunohistochemical were performed to analyze the ectopic 
osteogenesis and vascularization in the engineered periosteum. 
 
2.3.3 In vivo test for osteogenesis and vascularization in a skull 
defect model   
28 SCID mice were used for this experiment.  On the skull of each mouse, a hole 
defect was created using a dental drill. Scaffolds from each group mentioned above 
were implanted into the defect. Defects without implants were included as negative 
control. After 4 weeks, the defect-implant complex was harvested. Then the Micro-CT 
scanning analysis, histological and immunohistochemical were performed to analyze 
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the orthotopic osteogenesis and vascularization in the engineered periosteum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21
CHAPTER 3 LITERATURE REVIEW 
3.1 THE HISTOLOGICAL STRUCTURE OF PERIOSTEUM 
Periosteum is a dense connective tissue membrane covering the outer surface of all 
bones except the joint of long bones. It attaches tightly to various bone surfaces 
through Sharpy’s fibers, forming a thin but tough membrane.  The Sharpy’s fibers 
represent a direct continuation of the periosteal collagen fibers around which the 
cortical lamellae have grown [9].  Histologically the periosteum is thought to consist 
of two or three distinct layers [10-11].  In the “two layer” theory (Fig. 1), the 
periosteum consists of an outer fibrous layer which contains fibroblast, blood vessels, 
sensory and sympathetic nerve fibres, collagen fibers and extracellular matrix [12];  
The inner layer, referred to as the cambium layer, serves as a reservoir of 
undifferentiated progenitor cells able to differentiate into chondrogenic and 
osteoblastic cell lineages [13-15].  Osteogenic progenitor cells from the periosteal 
cambium layer may work with osteoblasts in initiating and driving the cell 
differentiation process of bone repair characterized by the development of the initial 
fracture callus and subsequent remodeling [16].  Periosteum can be described as an 
osteoprogenitor cell-containing bone envelope, capable of being activated to 
proliferate by trauma, retroviruses, tumors, and lymphocyte mitogens [17].  
 
 
Figure 1. An illustration of the structure of two-layered periosteum 
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Studies of the periosteum ultrastructure suggest it is made up of three discrete zones 
[11].  Zone I has an average thickness of 10 to 20 µm consisting predominantly of 
osteoblasts representing about 90% of the cell population, while collagen fibrils 
occupy 15% of the volume[11].  Transmission electron microscopy (TEM) pictures 
have revealed a supraosteoblast layer consisting of smaller, more compact cells 
containing large quantities of endoplasmic reticulum [11].  In zone II, fibroblasts and 
collagen make up half the volume in roughly equal proportions of 25% each, while 
capillary networks are around 15% of the volume [11].  The predominant cell type in 
zone II are fibroblasts, with endothelial cells being most of the remainder.  Zone III 
has the highest volume of collagen fibrils and fibroblasts compared to zones I and II 
[11].  Fibroblasts take up more than 90% of all cells in zone III.  Interestingly, 
fibroblast cells display morphological difference across the three zones.  In zone I 
the fibroblast-like cells adjacent to the osteoblasts are less numerous and have a lower 
surface density combined with a smaller cell volume and lower cell-to-volume ratio.  
Hence, they can be defined as more compact and isodiametric than normal fibroblasts 
[18]. Although slight differences exist between the “two layer” and “three layer” 
periosteum theories, one common characteristic feature of periosteum is that 
periosteum consists of an inner cambium layer and an outer vascularised and 
innervated fibrous layer. 
 
The structure of periosteum varies with age [19] .  In infants and children it is thicker, 
more vascular, active and loosely attached, while in adults or older people, it is 
relatively thinner, inactive and more firmly attached [9, 19-20]. The structure of 
periosteum is also found to be different at different periosteal sites in a rat model, e.g. 
diaphyseal or metaphyseal site [19]. The metaphyseal periosteum seems thicker and 
more cellular than the diaphyseal periosteum, and this difference is more obvious in 
older rats [19]. The differences in periosteum at different periosteal sites are also 
reported in osteoposis [10, 21].   
 
Periosteum is described as a well vascularised ‘‘osteogenic and/or chondrogenic 
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organ’’ [9].  It provides blood circulation to bone, especially the cortical bone [18] 
and is regarded as the “umbilical cord” of bone [22].  Stripping periosteum from the 
diaphysis typically destroys the arterial nutrient supply to bone [20].  The 
vasculature system of periosteum was first studied in detail by Zucman and later by 
Brookes [20].  Brookes’s studies showed that the capillaries supplying blood to bone 
reside within the cortex linking the medullary and periosteal vessels. Some authors 
have argued that the blood supply of periosteum has a number of features analogous 
to the blood supply of skin [23].  In skin, blood vessels in the dermal area provide 
nutritions and oxygen, and remove metabolic wastes from dermis and epidermis. 
 
Some reports have been published about the neurological aspects of bone and 
periosteum [24-26].  It has been reported that sympathetic and sensory nerves are 
prominent in the periosteum of mammalian bones and exist among blood vessels and 
osteogenic cells in these areas [24-26]. Sympathetic innervation of periosteum and 
bone contributes to the regulation of bone cell activity and, therefore, the equilibrium 
between bone modeling and remodeling [27].  It is known that surgical and chemical 
sympathectomy can both modulate bone cell function.  However, the sympathetic 
nervous system (SNS) can give rise to both anabolic and catabolic effects [28-31] and 
its role in regulating bone remodeling is, therefore, controversial. For example, some 
researches reported that if bone is deprived of its sympathetic innervation, bone 
deposition and mineralization is reduced and bone resorption increases [31], while in 
some other reports a sympathectomy impairs bone resorption [28]. Sensory nerves 
also appear to be important in normal bone metabolism and in bone fracture repair 
[32].  Increased sensory and sympathetic innervation of fracture calluses has been 
reported in animal experiments [26].  These findings suggest that innervation of 
bone is involved in both normal bone metabolism as well as fracture repair. 
  
3.2 THE ROLE OF PERIOSTEUM IN BONE FORMATION 
By publishing the article “Sur le Development et la Cruedes Os des Animaux” in 1742, 
Duhame can claim credit as the first investigator to study the osteogenic potential of 
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periosteum [18].  In a number of animal experiments he placed silver wires under the 
periosteum of long bones and revealed that after several weeks of implantation the 
wires were embedded in a bonelike matrix.  A century later another French surgeon, 
Ollier, discovered, while working with bone grafts in animals and human, that 
transplanted periosteum could induce de novo bone formation [18].  More recently 
the osteogenic/chondrogenic capacity of periosteum, and related mechanisms, have 
been confirmed and the underlying biology is better understood through a number of 
studies [33-35]. 
 
During embryogenesis there are two distinct patterns of in vivo bone formation, in 
both of which the periosteum play an indispensable role namely intramembranous 
and endochondral ossification.  Irregularly shaped bones, such as those in the 
craniofacial area, are formed through intramembranous patterning whereas regularly 
shaped long bones, such as the extremities, are formed by endochondral ossification.  
During intramembranous ossification, the mesenchymal cells first differentiate into 
osteoprogenitor cells forming a primitive periosteum together with surrounding 
fibroblasts.  After osteoprogenitor cells in periosteum differentiate into osteoblasts, 
bone formation process takes place. Together with the secretion and 
bio-mineralization of osteoids, osteoblasts are embedded and become osteocytes, and 
the new bone tissue wrapped in periosteum appears. During endochondral ossification 
chondrocytes and perichondreum also develop from mesenchymal cells and results in 
the formation of chondra which has a primitive configuration of bone. The 
perichondreum of the diaphysis transforms into periosteum and forms cortical bone 
layers over chondra, after which ossification of chondra takes place until all chondral 
tissues have been replaced by mineralized bone tissues with the exception of those 
chondra covering the joint or in the epiphyseal plate.  In adults the bone-forming 
potential of periosteum is reactivated by trauma, infection and also in some tumors.  
A number of studies have shown that periosteum regenerates both cartilage and bone 
from its progenitor cells within the cambium layer [36-38]. 
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3.3 THE ROLE OF PERIOSTEUM IN BONE HEALING 
In classical histological terms fracture healing has been divided into direct (primary) 
and indirect (secondary) fracture healing[39].  Direct fracture healing occurs when 
there is an anatomical reduction of fracture fragments by rigid internal fixation and 
decreased intra fragmentary strain[39].  This process involves a direct attempt by the 
cortex to reestablish new haversian systems by the formation of discrete remodeling 
units known as “cutting cones” in order to restore mechanical continuity [39].  
During this process little or no periosteal response is noted (i.e. no callus formation).  
The major parts of fractures heal through indirect fracture healing.  The indirect 
process basically reiterates the intramembranous and endochondral ossification 
processes as described above.  During intramembranous fracture healing the process 
involves no cartilage formation but rather direct bone callus (hard callus) 
development via osteoprogenitor cells from periosteum differentiating into osteoblasts.  
In the case of more severe fractures with associated haemorrhaging, both 
intramembranous and endochondral ossification is involved in the fracture healing 
process.  Haematomas in the fracture site will activate an acute inflammatory 
response that is followed by angiogenesis and cartilage formation that will finally be 
replaced by bone callus. During the bone healing process, mesenchymal cells are 
supplied from periosteum, endosteum, and bone marrow.  Several studies indicate 
that central to the healing response is the supply of mesenchymal cells from 
periosteum [10, 15, 40-44]. Uddstromer and colleagues have shown that periosteum 
play the most important role in fracture healing [45-46]. Oni and colleagues 
demonstrated fracture healing was delayed when periosteum was removed [47-48].  
Other factors appear to play only minor roles in fracture healing [49-50]. 
 
3.4 PERIOSTEUM ENGINEERING STRATEGIES 
Currently, periosteal grafting (auto- or allo-) is accepted as the standard for 
periosteum replacement therapy to aid the repair of bone and/or cartilage tissue. 
Similar to other tissue transplantation process, a periosteal graft serves as a cell source, 
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scaffold for delivering and retaining cells and a source of local growth factors critical 
for regeneration [51-53]. Although they have been fairly promising, the use of 
periosteal grafts is not without limitations. Auto-grafting poses limitations of donor 
site morbidity, supply shortage and unpredictable resorption of graft, while 
allo-grafting poses immunogenic rejection and possible disease transmission [54]. 
 
As recently pointed out in a review by Zhang et el, periosteum engineering could 
assist in structural de novo bone formation and is therefore a promising method for 
bone defect restoration [55]. To engineer a periosteum, three basic strategies could be 
used: acellular bioactive membrane; membrane seeded with osteogenic cells; 
membrane seeded with both osteogenic and angiogenic cells. Most studies at the 
present use acellular bioactive membranes or membranes carrying osteogenic cells.  
Encouraging results were achieved by Neel [56] when a periosteal replacement 
membrane was used for bone graft containment at the allograft-host junction. The 
membrane, however, was acellular. Koji Hattori [57] was able to demonstrate healing 
of a severe open fracture by applying bio-artificial periosteum composed of 
osteogenic cells and a collagen sponge. In another study, submucosa from the small 
intestine was used to mimic periosteum onto which bone marrow stromal cells 
(BMSCs) were seeded [58].  The obvious drawback of this approach is that scaffold 
materials have to be sourced from the small intestine necessitating the need for an 
operation to harvest donor materials. As these engineered periosteum are either 
acellular or single cell carrying, they differ considerably from the structure of natural 
periosteum; the cell viability, stability, long-term function and clinical applicability of 
these artificial periostea are therefore in doubt [56-58]. Although much work has been 
done under the subject of periosteum [18-19, 35, 59], few, if any, references were 
found addressing bi-layered engineered periosteum which contains both osteogenic 
and angiogenic cells in particular, not to mention an in vivo assessment of any such 
constructs.   
 
3.5  SCAFFOLD MATERIALS CURRENTLY USED IN TISSUE 
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ENGINEERING 
3.5.1 Bioceramics: Hydroxyapatite (HA) and Beta-Tricalcium 
Phosphate (β-TCP) 
Mineral-based scaffolds, or bioceramics, have long been recognized as potent 
osteoconductive materials for hard tissue engineering such as bone [60]. This 
application is based on the fact that bioceramics are chemically similar to the calcium 
phosphate found in natural bone, typically in the form of hydroxyapatite (HA) [4, 60].  
In natural bone the three main components are calcium phosphate, water and collagen 
(predominantly type I collagen), together with other organic materials in smaller 
quantities, such as non-collagenous proteins, polysaccharides, and lipids [61].  
Calcium phosphate in bone is in the form of crystallized HA and amorphous calcium 
phosphate (ACP).  The HA crystals are needle or plate shaped and are deposited 
along and parallel to the collagen filaments [61]. 
 
A key feature of bioceramics, their bioactivity, makes these materials attractive 
candidates as scaffolds in hard tissue engineering.  Most researches agree, however, 
that HA is primarily osteoconductive rather than osteoinductive although this is a 
topic of some debate [1, 4, 62].  HA do not appear capable of inducing new bone 
formation in the absence of osteogenic cells or growth factors such as BMPs [62].  
Also, HA does not readily biodegrade, retarding the bone replacement by host tissues, 
something which limits the material’s application in some circumstances [63].  In 
clinical cases, an HA scaffold can still persist for 5 years after implantation[64].  
 
β-TCP is another type of calcium phosphate found in the human body, which is highly 
biocompatible, as well as bioactive. Although β-TCP also appears to be primarily 
osteoconductive, the material biodegrades more readily than HA. Once it degrades it 
is resorbed by the body and is gradually replaced by host tissue [65].  The 
mechanical strength of β-TCP is relatively weaker than that of HA [66].  In order to 
optimize the application of both HA and β-TCP, some researchers have mixed them to 
form a HA-TCP composite so that resorption time and mechanical properties of the 
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composite material can be adjusted by varying the ratios of HA to β-TCP [66-67]. 
 
HA and β-TCP are both porous materials.  The pore size, porosity and inter- 
connections between pores directly influence their osteoconductivity, osteogenic cells 
ingrowth, vascularisation, osseointegration and scaffold material resorption [68].  
The optimal pore size for bone ingrowth is thought to be 200-400µm [68].  A higher 
total porosity coupled with a greater degree of interconnections among pores will 
make the material better suited for bone reconstruction [62].  However, greater 
porosity poses a problem in that the inherent porosity of the bioceramic scaffolds also 
renders the constructs brittle and thus prone to stress fracture when placed in load 
bearing situations.  In an effort to increase the strength of these bioceramics and, 
more importantly, mimic the chemical composition and structure of natural bone 
tissue, collagen and other biodegradable synthetic polymers are bound to bioceramics.  
These composite materials have been found to have osteoconductive properties [2, 
69-70]. 
 
3.5.2 Natural polymer biomaterials: Collagen 
Collagen is the most abundant protein in mammalian tissues, accounting for up to 
one-third of all proteins [71].  Collagen fibers are the main component of the 
extracellular matrix in various tissues, especially the connective tissue such as dermis, 
tendon, bone, cartilage, mucosa and periosteum.  The main function of collagen is as 
a mechanical reinforcement of the connective tissue. 
 
The individual polypeptide chains of collagen contain 20 different amino acids and 
the precise composition varies among different tissues [72].  Variations in the amino 
acid sequence generate the different types of collagen: type I, II, III X and XIX and 
the most common types are types I, II and III.  Type I collagen is dominantly found 
in skin, tendon, periosteum and bone; type II is the main collagen type in cartilage, 
whereas type III is found in blood vessels.  
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Collagen is increasingly being used as a scaffold material in both soft and hard tissue 
engineering.  It is used to repair tissues such as skin, blood vessel, bone and cartilage 
given it is a natural polymer already existing in the body and has excellent 
biocompatible properties and bioactivity [73-76]. Collagen is also easily biodegraded 
and resorbed by the body and allows for optimal cell attachment.  The main 
disadvantage of collagen is its low mechanic strength, especially compared with bone.  
To increase its mechanical property, collagen is therefore highly crosslinked or 
combined with other materials, such as collagen-glycosaminoglycans for skin 
regeneration [77], and collagen-HA for bone repairing [69].  When collagen is bound 
with growth factors (e.g. BMPs, VEGF, FGF, TGF-β) and/or seeded with various 
pluripotent cells, its bioactivity inducing tissue growth and regeneration is enhanced 
[5, 78-79].  One major concern about the application of allogeneic or xenogeneic 
collagen is its potential immunogenicity.  However, studies have shown that adverse 
immunological responses only occur in rare cases and generally settle within a few 
months never lasting longer than 1 year, especially in the case of type I collagen [1, 
80].  Premature resorption or other adverse effects of collagen implantation have 
rarely been reported and the combined use with immunosuppressants has been shown 
to be effective [80-81]. 
 
3.5.3 Synthetic biodegradable polymer biomaterials: 
poly(glycolide), poly(lactide) and poly(lactide-co-glycolide) 
Poly(glycolide) (PGA), poly(lactide)(PLA) and poly(lactide-co-glycolide)(PLGA) are 
aliphatic polyesters and the most commonly used synthesised biodegradable polymer 
scaffold materials.  The US Federal Drugs Administration has already approved their 
use in certain human applications [68].  Poly(glycolide) (PGA) is synthesized from 
dimerization of glycolic acid, and is the simplest linear aliphatic polyester. PGA fibers 
show high strength and modulus because of their high degree of crystallinity [82].  
PGA was developed as the first totally synthetic absorbable suture and has been 
marketed as DexonTM since 1960s by David and Geck [82].  Sutures of PGA lose 
about 50% of their strength after two weeks and 100% after four weeks and are 
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completely absorbed within 4-6 months [82-83].  PGA has successfully been used as 
scaffold material in skin, tendon, cartilage and bone reparation [84-86].  Since the 
glycolide can be copolymerized with other monomers, such as lactide and 
trimethylene carbonate, PGA is often involved in yielding copolymer with various 
mechanical and biodegradation properties for different applications [82, 87-88]. 
 
Poly(lactide) (PLA) is synthesized in a similar way to PGA by the dimerization of 
lactic acid.  Lactic acid is a chiral molecule with two stereo-isometric forms: D-LA 
and L-LA referred to as PDLA and PLLA respectively.  Both form crystalline 
polymers.  PLLA is more commonly used than PDLA because the biodegradation 
product of PLLA, namely L-LA, is the naturally occurring isomer of lactic acid in the 
human body[82]. What is more, as a biodegradable material, PLLA has a satisfactory 
biocompatibility profile in vitro[82]. It is non-toxic and stimulates only a mild 
inflammatory response[82].  The hydrolysis product L-LA is the normal intermediate 
of carbohydrate metabolism and will not accumulate in vital organs [82].  It has been 
successfully used in the reconstruction of bone, articular defects, for suture materials, 
drug carriers and fixation devices [1, 60, 72, 82, 89].  The degradation time of PLLA 
is longer. PLLA has been reported to take up to 3 years to be completely absorbed 
[90].  In order to overcome this problem, D-LA has been added as a co-monomer to 
obtain the copolymer PDLA which has a lower crystallinity than PLLA and 
consequently a higher rate of degradation [82]. 
 
Poly(lactide-co-glycolide) (PLGA) is synthesized through copolymerizing lactide and 
glycolide, the mechanical and biogradation properties of which are based on the ratio 
of individual monomers in the composite. A copolymer of 50% glycolide and 50% 
D-LA degrades faster than both homopolymers [91]. The degradation rate strongly 
depends on the structure of the copolymers[91]. Copolymers of 25%-70% L-LA with 
glycolide are amorphous due to the disruption of the regularity of the polymer chain 
by the other monomer[91].  Therefore, these copolymers show much greater 
degradation rates than either individual homopolymers [91].  PLGA has been used 
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with different cell types and/or growth factors to enhance the tissue regeneration and 
reparation, especially in blood vessel, bone, cartilage engineering [8, 92-93].  A 
modified PLGA could provide attachment sites for specific peptides, such as 
Arg-Gly-Asp (RGD) sequences thus modulating cell adhesion and growth [94].  A 
major concern about the application of these synthetic polymers is the chemicals 
(additives, traces of catalysts, inhibitors etc.) and monomers (glycolic acid, lactic acid) 
released from polymer degradation, which may induce local and systemic host 
reactions that cause clinical complications [69].  Lactic acid, the by-product of PLA 
degradation, is reported to potentially create an adverse cellular response at the 
implant site by reducing the local pH triggering the release of prostaglandin E2 (PEG2), 
a bone resorbing and inflammatory mediator, by human synovial fibroblasts and 
murine macrophages [95].  However, the addition of carbonate to the implant seems 
to be a potential way of stabilizing the local pH [96].  Some potential toxic residues 
during chemical crosslinking treatments (e.g. glutaraldehyde) may also make this 
crosslinking technique less desirable for implantable devices[97-98].  
 
3.6  CELL DELIVERY METHODS 
3.6.1 Cell delivery through porous scaffold materials 
One of the most commonly used cell delivery methods is to seed cells into solid 
porous scaffolds.  Following implantation these scaffold–cell constructs stimulate 
the formation of reparative tissue while maintaining adequate integrity [99].  In 
skeletal tissues cells are distributed within a dense ECM made up of collagens, 
proteoglycans, a complex mixture of phosphoproteins and other inorganic 
materials[99].  For regeneration of these types of tissues a homogeneous spatial 
distribution of cells within all areas of the reparative implant is preferable [99]. 
Despite seeding cells on flat surfaces is easy to perform, on three-dimensional porous 
constructs it will be more difficult [99]. 
 
Seeding cells onto porous membranes or solid scaffolds rarely results in an even cell 
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distribution [99].  Pore size, porosity and inter-pore connection are the main factors 
influencing cell distribution in three dimensional porous scaffolds.  Sufficient pore 
size allows cells to migrate or adhere to the surface layer of a material, whereas 
interconnecting pores permit cells to grow into the interior region of the scaffold [99].  
Interconnecting porosity will also facilitate nutrient supply into the central region of 
engineered transplants [99].  With currently available engineered bone implants, 
cells receive their nutrition through diffusion before new blood vessels are formed to 
support tissue formation [99].  Consequently, the optimal geometries and dimensions 
of tissue-engineered bone for orthopedic applications are still under investigation. 
 
Adhesion of cells to the material surface is the first step in construction of a cell and 
scaffold complex.  Attachment to surfaces activated with biomimetic peptides or 
growth factors can induce cell proliferation, differentiation and tissue maturation[99] 
[100].  Mesenchymal cells, when expanded in a monolayer culture, will undergo a 
process of phenotypic and functional dedifferentiation [99].  On the other hand, three 
dimensional cell cultures provide the advantage of independent cell growth and 
maintaining the differentiated phenotype [99, 101].  Evidences have suggested that 
anchorage independent growth in a semisolid medium is superior for chondrogenic 
differentiation of mesenchymal stem cells (MSCs) [99].  Osteogenic differentiation 
of cells can be positively influenced by strong adhesion to surfaces[99].  However, 
recent studies have shown osteogenic differentiation of MSCs in hydrogel cultures 
without the conventional methods of cell attachment on biomimetic surfaces [99, 
102]. 
 
3.6.2 Cell delivery through homogeneous scaffolds 
Homogeneous scaffolds refer to polymer solutions that subsequently form gels.  
Collagen, hyaluronate, fibrin, agarose, alginate and chitosan are commonly used 
embedding gels in tissue engineering applications[99].  Cells can distribute evenly 
and 3-dimensionally in these type of scaffolds, which is why this is a preferred pattern 
for tissue regeneration [99].  The main disadvantage of these scaffolds is the 
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immobility of the cells and coupled with weak mechanical properties, limiting their 
application in load-bearing tissue reparation, such as bone.  However, when 
combined with other materials, such as HA, TCP, or synthetic polymers, homogenous 
scaffolds can be used successfully in hard tissue engineering [69-70]. 
  
3.6.3 Cell delivery through injectable scaffolds 
Bioresorbable and injectable polymers can more easily fill defects of all shapes and 
sizes compared to prefabricated scaffolds and require only minimal surgical 
intervention for implantation. In order to provide the mechanical strength required for 
orthopedic applications, injectable polymers must be polymerized or crosslinked in 
situ, something which places a major constraints on these material’s usefulness.  All 
reagents involved in the polymerization, as well as the reaction products, must be 
non-toxic.  Furthermore, the heat release and local pH variation must be within the 
tolerance of cells in implants and surrounding tissues in order to protect cells from 
damage [68]. 
 
Injectable cell delivery systems will provide early mechanical stabilization by in situ 
polymerization and could be used to treat irregularly shaped joint defects [99, 
103-104].  Thermoreversible, biocompatible in situ gelling, formulations have been 
tested for chondrocyte delivery [99, 105].  Recent studies have evaluated the 
suitability of injectable carriers to support MSC function [99, 106].  However, it is 
still uncertain if injections of MSCs into the joint cavity can be directed into 
regenerative healing and produce significant clinical improvement for the patient [99, 
107].  Chondrocyte transplantation into sites other than articular defects has so far 
been unsuccessful in immunocompetent animals[99].  In irregular bone defects, 
injectable bone forming cell-matrix composites might be a more appropriate method 
than conventional scaffolds[99].  Early stabilization could be achieved using 
injectable gels (fibrin or collagen) in combination with tricalcium phosphate or 
hydroxyapatite particles[99, 108]. Similarly, if cell anchorage is achieved before in 
vivo delivery, injectable carrier beads with attached cells can be used [99, 109]. 
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3.7  BONE MARROW MESENCHYMAL CELLS  
3.7.1 The nature and biology of bone marrow mesenchymal cells 
Bone marrow cells comprise a dual system of stem or progenitor cells: the 
hematopoietic cell system and non-hematopoietic bone marrow mesenchymal stem 
cell system (BMSCs) [110-111].  Hematopoietic stem cells (HSCs) in bone marrow 
are the reservoir of various blood cells, such as erythrocytes, leukocytes, macrophages 
or platelets, and they also contain endothelial progenitor cells (EPCs) which can 
become mature endothelial cells when needed [112-113]. BMSCs, when cultured in 
vitro, are negative for CD45, CD14, CD31 and CD34 but positive for CD105, CD 44, 
CD73 and CD90. They are a mixture of multipotent progenitor cells which can 
differentiate into various other mesodermal cells, such as osteoblasts, chondrocytes, 
fibroblasts or adipocytes [114].  Because there is very little extracellular matrix 
(ECM) present in bone marrow, gentle mechanical disruption can easily dissociate 
stromal and hematopoietic cells into a single-cell suspension.  When these cells are 
cultured in vitro, BMSCs rapidly adhere and can be easily separated from the 
nonadherent hematopoietic cells by repeated washing.  BMSCs form colonies and 
are therefore defined as Colony Forming Units—Fibroblasts (CFU-Fs), indicating that 
each colony derives from a single proliferating progenitor [115]. The BMSCs consist 
of heterogeneous cell populations, typically exemplified by a broad range of colony 
sizes, representing varying growth rates, and different cell morphologies ranging from 
fibroblast-like spindle-shaped cells to large flat cells [115].  Furthermore, if such 
cultures are allowed to develop for up to 20 days, phenotypic heterogeneity is also 
observed [110].  A method to distinguish the subsets of BMSCs with the most active 
replication and individual differentiation potential would certainly be very important 
for both theoretical and applicative reasons. Several laboratories have developed 
monoclonal antibodies using BMSCs as immunogens in order to identify one or more 
markers suitable for identification and sorting [116-118].  However, to date the 
isolation of a “pure” population of multipotent marrow mesenchymal stem cells 
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remains elusive. 
 
3.7.2 The application of BMSCs in angiogenesis and osteogenesis  
As mentioned above, bone marrow cells are a mixture of multipotent cells with the 
latent ability to differentiate into different cell lineages depending on the cell culture 
environment, a fact that makes applying bone marrow cells as a cell source for 
various tissue engineering and cell-delivery therapy possible. For in vitro 
vasculargenesis and angiogenesis there are several potential cell sources, e.g. mature 
endothelial cells (MEC, or EC) from vessels, such as adult tissue veins or arteries; 
MEC from human umbilical cord veins (HUCV); endothelial progenitor cells (EPC) 
from adult bone marrow cells , adult peripheral blood, fetal umbilical cord blood or 
some tissues such as fat, muscle or neural.  MECs, especially those from the HUCV, 
are often used as a cell source for in vitro angiogenesis [119-120].  A limiting factor 
with these cells is that allogeneic MECs may induce immunological responses 
through resting T-cells [121].  EPCs are actually a fraction of leukoctyes found in 
peripheral blood and bone marrow. Bone marrow cells are a valuable source of 
autologous and immunologically neutral cells for vasculogenesis and angiogenesis 
[122].  Although the phenotype of EPC has not been completely clarified, they are 
now thought to be CD133+ / CD34+ / VEGFR2+ (Flk-1/KDR) / MUC18+ / 
VE-Cadherin+ and CD45- / CD14- cells.  MECs on the other hand lose the CD133 / 
MUC18 markers, but express CD31 / CD34 / VEGFR2 (Flk-1/KDR) / VE-Cadherin 
markers [122-124].  MECs also contain vWF (von Willebrand factor) in the 
cytoplasmic granules named Weibel-Palade bodies. Thus, CD133+/ 
MUC18+/CD34+/VEGFR2+(Flk-1/KDR) cells are more likely to represent the EPCs, 
while CD31+/CD34+/VEGFR2+(Flk-1/KDR)/ vWF+ (Weibel-Palade body) may 
identify the MECs.  Based on these markers EPCs and MECs could be selected out 
and distinguished from each other in peripheral blood or bone marrow.  It is still 
almost impossible to completely purify EPCs from the mononuclear cells, even if 
EPCs markers are identified, since EPCs and haematopoietic progenitor cells descend 
from the same precursor cells and have many cell markers in common.  A recent 
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study suggests that there may be another way to characterize ECs, especially those 
derived from the bone marrow [112].  Despite the broad overlap in both antigenic 
and functional assays, there appears to be three characteristics unique to ECs: i) eNOS 
(NO synthase III) is confined to ECs; ii) only ECs can integrate into tube-like 
structures formed by HUVEC; iii) only ECs can significantly stimulate tube formation 
by HUVEC [113].  Although the number of EPCs in bone marrow or peripheral 
blood is very low, when isolated and expanded in culture, EPCs proliferate rapidly 
and can be expanded for at least 20 population doublings compared with ECs [125].  
Cultured with certain cytokines in gelatin-coated dishes, such as VEGF and bFGF, the 
EPCs can differentiate into ECs and exhibit a cobblestone morphology characteristic 
of ECs [126]. 
 
As multipotent adult progenitor cells (MAPCs) and a pool of cells committed to 
various lineages and stages of differentiation, the BMSCs contain potentially 
osteogenic colonies [110-111].  These colonies can be referred to as “skeletal stem 
cells” meaning they are ancestors to mesodermal supportive tissues such as bone, 
cartilage, fibrous tissues, adipocytes, smooth muscle cells and so on [111].  These 
“skeletal stem cells”, however, stay in different commitment stages of differentiation. 
Some are tripotential and are able to differentiate into osteoblasts, chondrocytes, and 
adipocytes in vitro; others are bipotential differentiating only into a 
chondrogenic-osteogenic phenotype, whereas a third group comprises only osteogenic 
clones [127].  Interestingly, it appears that, over a prolonged time in culture, the 
differentiation potential is reduced and that tripotential clones progressively lose 
adipogenic, then chondrogenic, and finally osteogenic potential, suggesting a 
preferential commitment of the progenitors towards the osteogenic phenotype [127].  
Many researches have shown the osteogenic abilities of BMSCs, both in vitro and in 
vivo, and applied it to bone defect restoration [128-129].  There is little doubt that 
following ex vivo expansion under certain conditions, BMSCs are able to differentiate 
into osteogenic progenitor cells and finally osteoblasts.  These osteoblasts are able to 
regenerate segments of bone lost through trauma or disease by direct orthotopic 
 37
placement in conjunction with appropriate scaffolds, most commonly those containing 
hydroxyapatite/tricalcium phosphate (HA/TCP). 
 
 
3.8  SUMMARY 
Developing bone substitute materials for bone defect repair has inspired orthopedic 
surgeons, bioengineering scientists and bone biologist to work collaboratively in order 
to design and develop the promising products for clinical applications. Tissue 
engineered periosteum is aimed to mimic the natural structure of periosteum to guide 
bone formation in a physiological manner. This review summarizes anatomical 
structure and physiological functions of periosteum in bone development and defect 
healing. The potential technology for periosteum scaffold fabrication, potential 
applicable scaffold materials and cells for cell-scaffold complex construction and 
strategies to engineer functional periosteum are reviewed and discussed based on 
current publications and the laboratory work conducted in our research projects. 
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Abstract 
In both physiological and pathological processes, periosteum plays a determinant role 
in bone formation and fracture healing. However, no specific report is available so far 
focusing on the detailed structural and major cellular differences between the 
periostea covering different bone surface in relation to ageing. The aim of this study is 
to compare the structural and cellular differences in diaphyseal and metaphyseal 
periostea in different-aged rats using histological and immunohistochemical methods. 
Four female Lewis rats from each group of juvenile (7-week old), mature (7-month 
old) and aged groups (2-year old) were sacrificed and the right femur of each rat was 
retrieved, fixed, decalcified and embedded. 5 µm thick serial sagittal sections were cut 
and stained with Hematoxylin and Eosin, Stro-1 (stem cell marker), F4/80 
(macrophage marker), TRAP (osteoclast marker) and vWF (endothelial cell marker). 
1mm lengths of middle diaphyseal and metaphyseal periosteum were selected for 
observation. The thickness, total cell number and positive cell number for each 
antibody were measured and compared in each periosteal area and different-aged 
groups. The results were subjected to two-way ANOVA and SNK tests. 
The results showed that the thickness and cell number in diaphyseal periosteum 
decreased with age (p<0.001). In comparison with diaphyseal area, the thickness and 
cell number in metaphyseal periosteum were much higher (p<0.001). There were no 
significant differences between the juvenile and aged groups in the thickness and cell 
number in the cambial layer of metaphyseal periosteum (p>0.05). However, the 
juvenile rats had more Stro1+, F4/80+ cells and blood vessels and fewer TRAP+ cells 
in different periosteal areas compared with other groups (p<0.001). The aged rats 
showed much fewer Stro1+ cells, but more F4/80+ ,TRAP+ cells and blood vessels in 
the cambial layer of metaphyseal periosteum (p<0.001). 
In conclusion, structure and cell population of periosteum appear to be both 
age-related and site-specific. The metaphyseal periosteum of aged rats seems more 
destructive than diaphyseal part and other age groups. Macrophages in the periosteum 
may play a dual important role in osteogenesis and osteoclastogenesis. 
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Introduction 
The periosteum is a type of connective tissue developed from mesodermal cells 
during the embryonic development. It is tightly attached to various bone surfaces 
through Sharpy’s fibres, forming a thin but very tough membrane. In both 
physiological and pathological processes, periosteum plays a determinant role in both 
bone formation and fracture healing in addition to the involvement of other important 
factors such as growth factors and mechanical loading [9, 20, 35]. The periosteum 
contains progenitor cells both osteogenic and chondrogenic in nature, as well as other 
related bioactive factors, and is highly vascularised [9, 14, 23]. Transplantation of 
autogenous and allogenous periosteum have been applied successfully to repair 
various-sized bone or cartilage defects, in particular to large bone defects [7, 36-37, 
130-131]. However, the availability of periosteum, morbidity associated with harvest 
and immunological concerns are still barriers against large scale in vivo application of 
periosteum transplantation. Interestingly, the progenitor cells in the bone marrow and 
periosteum have been successfully applied in bone tissue engineering with various 
scaffold materials [18, 115, 128, 132-135]. Some researchers have attempted to make 
artificial periosteum by seeding progenitor cells onto a membrane and achieved 
positive results in repairing bone defects in vivo [56-57]. However, current artificial 
periosteum, which is based on single type of cell structure, is still far from clinical 
application, primarily due to the questionable cell viability, stability and long-term 
function. One of the major challenges in tissue-engineered periosteum is to form the 
cellular structures similar to native periosteum, which can represent the stage of active 
bone formation. Therefore, it is imperative to understand the cellular structures of 
periosteum and their relationship during bone development and ageing.  To date, 
however, no clear histological basis is available for the selection of donor-site or 
age-related periosteal grafts. 
Previous studies have revealed that periosteum consists of two different layers [10]. 
The outer fibrous layer is composed of fibroblasts, collagen, elastin fibrers, nerve, and 
microvascular network. The inner cambial layer is highly cellular containing 
mesenchymal stem cells, fibroblasts, osteogenic progenitors and osteoblasts. However, 
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no study has documented the detailed structural and specific cellular differences 
between the periosteum on different bone surface, such as the difference between 
metaphyseal and diaphyseal periosteum.  
Age is another important factor affecting the structure and function of periosteum. 
Some age-related changes in periosteum have been reported including decreased 
periosteal fibroblast number, fibrous layer thickness, osteoblast number, collagen 
formation, osteoid zones and vessel density throughout the periosteum [11, 136-138]. 
Depending on the locations of bone formation or resorption periosteum shows 
corresponding structural changes with ageing [136, 139]. However, the detailed 
information about the age-related structural and cellular changes in different 
periosteal areas is still unclear. We hypothesize that age-related changes in periosteum 
are also site-specific. Therefore, the distribution of mesenchymal stem cells, 
macrophages, osteoclasts, blood vessels and structural changes in metaphyseal and 
diaphyseal periostea from the femurs of different aged rats were investigated in this 
study.  
 
Materials and Methods 
Animal samples and slices 
This study was carried out according to the guideline of the Animal Ethics Committee 
of the Queensland University of Technology. Three different aged groups of female 
Lewis rats were utilized with four rats in each group. The juvenile, mature, and aged 
groups were 7-week old, 7-month old, and two-year old rats respectively. The right 
femur of each rat was retrieved after the animals were sacrificed. The tissue samples 
were fixed with 4% paraformaldehyde for 12 hours at room temperature, then 
decalcified in 10% EDTA and embedded in paraffin. Serial sections of 5 µm thick 
sagittal slices were cut from the paraffin blocks using a microtome (Leica 
Microsystems GmbH Wetzlar, Germany). The slices near the central sagittal plane 
were used for subsequent experiments.  
 
Definition and selection of observed tissue areas 
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The diaphyseal and metaphyseal periostea were selected for the observation. The 
diaphyseal periosteum was selected from 1 mm length of periosteum in the middle of 
diaphyseal area and the metaphyseal periosteum was selected from 1 mm length of 
periosteum from metaphyseal area starting from the mesial border of growth plate on 
upper metaphysis.  
 
Structural observation  
Four slices from each rat sample were stained with Hematoxylin and Eosin (HD 
Scientific supplies Pty Ltd, Kings Park, NSW, Australia). The images were captured 
under ×200 magnification. The thickness of fibrous and cambial layers on the middle 
line perpendicular to the periosteum in each microscopic field and cell number of 
each layer throughout each periosteal area were measured using Axion software (Carl 
Zeiss Microimaging GmbH, Göttingen, Germany) under a microscope (Carl Zeiss 
Microimaging GmbH, Göttingen, Germany). The data from the four slices were 
averaged and recorded for subsequent analysis. 
 
Immunohistochemistry  
Four specific cell markers, Stro-1 (mouse anti-human, Chemicom International Inc., 
Temecula, CA, USA), F4/80 (Rat anti-mouse, ABR-Affinity BioReagents Inc., 
Golden, CO, USA), TRAP (tartrate-resistant acid phosphatase)(mouse anti-human, 
Lab Vision Co., Fremont, CA, USA) and vWF (mouse anti-human, Chemicom 
International Inc., Temecula, CA, USA), were utilized to identify mesenchymal 
stromal cells, monocytes/macrophages, osteoclasts and blood vessels in each 
periosteal sample of different-aged groups. To validate the results, each experiment 
was repeated at least three times.  
Prior to immunoperoxidase staining, endogenous peroxidase activity was quenched by 
incubating the tissue sections with 3% H2O2 for 20 minutes.  All sections were 
blocked with 10% swine serum for 1h. The enzymatic treatment was used to expose 
epitopes by incubating the slices with proteinase K (ready-to-use, DakoCytomation, 
CA, USA,) for 10 minutes at room temperature. Sections were then incubated with 
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optimal dilution of primary antibody Stro-1 (1:100), F4/80 (1:50), TRAP (1:20) and 
vWF (1:100) overnight at 4 0C. Sections were then incubated with a biotinylated 
swine-anti-mouse, rabbit, goat antibody (DAKO Multilink, CA, USA) for 15 minutes, 
and then incubated with horseradish perioxidase-conjugated avidin-biotin complex 
(ABC) for 15 minutes.  Antibody complexes were visualized after the addition of a 
buffered diaminobenzidine (DAB) substrate for 4 minutes.  The reaction was 
stopped by immersion and rinsing of sections in PBS.  Sections were then lightly 
counterstained with Mayer’s haematoxylin and Scott’s Blue for 40 seconds each, in 
between 3 minute rinses with running tap water.  Following this, the sections were 
dehydrated with ascending concentrations of ethanol solutions, cleared with xylene 
and mounted with a cover slip using DePeX mounting medium (BDH Laboratory 
Supplies, England). 
Controls for the immunohistological staining procedures included conditions where 
the primary antibody was omitted.  In addition, an irrelevant antibody (IgG), which 
was not present in the test sections, was used as a control. 
Under ×400 magnification, the positive cell number from each cell population in 
each periosteal area was counted using a microscope (Carl Zeiss Microimaging 
GmbH, Göttingen, Germany) and AxioVision software (Carl Zeiss Microimaging 
GmbH, Göttingen, Germany). Each measurement included three different slices and 
the average was recorded for subsequent analysis. To eliminate the effect of the 
difference in total cell number and periosteum thickness in different groups on the 
positive cell number and blood vessel counting, the Strol-1+, F4/80+, and TRAP+ cell 
numbers were normalized to the cell number per 100 total cells in each specific group. 
The blood vessel number was normalized to the vessel number in 0.03mm2 periosteal 
area. 
 
Statistical analysis 
All the data were analyzed according to the age of rats and the periosteal sites by 
two-way ANOVA using the General Linear Model and post-hoc testing performed 
using Student-Neuman-Keuls comparison (SNK) for group homogeneity.  The 
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significance level was set at p ≤ 0.05.  Analysis was performed using SPSS software 
(SPSS Inc, Chicago Il).  
 
Results 
Structural differences in different periosteal areas and aged groups 
The two-way analysis of variance model indicated that the age of rats and the 
periosteal sites both influenced, independently and interactively, the thickness and cell 
number in the periosteum (p<0.001). In diaphyseal periosteum, both thickness and 
cell numbers decreased with age in both cambial and fibrous layers (Fig.1). However, 
no significant differences were found in the thickness of the fibrous layer between 
juvenile and mature groups (p=0.39). There was no difference in cell numbers in the 
fibrous layer between mature and aged rats (p= 0.07) (Fig.1). Both the thickness and 
cell numbers in the cambial layer decreased significantly with age (p<0.001) (Fig.1).  
Compared to the diaphyseal area, the thickness and cell number in fibrous and 
cambial layers were significantly higher in metaphyseal periosteum (p<0.001) (Fig.1). 
In general，the metaphyseal periosteum of juvenile and aged animals was thicker and 
more cellular when compared with the mature group. Notably, there were no 
significant differences between the juvenile and aged groups in the thickness and cell 
numbers in the cambial layer of metaphyseal periosteum (p=0.07 for thickness and 
p=0.14 for cell number) (Fig.1). The mature rats had the thinnest and least cellular 
cambial layer in the metaphyseal area. The thickness of the fibrous layer in the 
metaphyseal periosteum from all three age groups was similar (p=0.09), while both 
mature and aged groups were much less cellular in this layer than the juvenile group 
(p<0.001) (Fig.1).  
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Figure 1. Diagrams and pictures (×200) of H&E observation of diaphyseal and 
metaphyseal periostea from different-aged groups. The thickness and cell number of 
the cambium layer in diaphyseal periosteum (Dia-c) decreased with age. No 
significant differences were found in the thickness of the diaphyseal fibrous layer 
(Dia-f) in juvenile and mature groups. There were no differences in cell numbers in 
the fibrous layer in mature and aged rats. There were no significant differences 
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between the juvenile and aged groups in the thickness and cell number in cambial 
layer of metaphyseal periosteum (Meta-c). The thickness of metaphyseal fibrous layer 
(Meta-f) from three aged groups was similar to one another, while both mature and 
aged groups were much less cellular in this layer than in the juvenile group. *: p<0.05. 
J: Juvenile; M: Mature; A: Aged.. 
A: diaphyseal periosteum from the juvenile group; B: diaphyseal periosteum from the 
mature group; C: diaphyseal periosteum from the aged group; D: metaphyseal 
periosteum from the juvenile group; E: metaphyseal periosteum from the mature 
group; D: metaphyseal periosteum from the aged group; (In pictures, B: bone tissue; P: 
periosteum; C: cambial layer; F: fibrous layer) 
 
Stro-1 expression in periosteum  
The normalized Stro-1+ cell number was used in this analysis. Site (p=0.04), age 
(p<0.001) and the interactions between site/age were also significant (p<0.001) in the 
model for Stro1 expression. In diaphyseal periosteum, Stro-1 was broadly expressed 
in the cambial and fibrous layers in juvenile rats (Fig. 2). Very few Stro-1 positive 
cells were found in either cambial or fibrous layers from mature and aged rats 
compared to the juvenile group (p<0.001) (Fig. 2).  
In the metaphyseal area, the juvenile rats had significantly more Stro-1+ cells in both 
the cambial and fibrous layers compared with the mature and aged rats (p<0.001) (Fig. 
2). In the fibrous layer of aged rats there were more Stro-1+ cells compared with the 
cambial layer and the fibrous layer of mature group (p<0.05). The mature and aged 
groups had similar number of Stro-1+ cells in the cambial layer. (Fig. 2). 
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Figure 2. Diagram and pictures (×400) of Stro-1+ cell distribution in different 
periosteal areas and age groups. Stro-1 was broadly expressed in both the cambial and 
fibrous layers of diaphyseal periosteum (Dia-c and Dia-f) from juvenile rats. Very few 
Stro-1+cells were found in diaphyseal cambial and fibrous layers from mature and 
aged rats in comparison with the juvenile group. No significant difference was found 
in the Stro-1+ cell numbers in metaphyseal periosteum (Meta-c and Meta-f) of the 
juvenile and mature rats when compared with the diaphyseal area, while both mature 
and aged groups had much fewer positive cells than the juvenile group in this area. *: 
p<0.05. J: Juvenile; M: Mature; A: Aged. 
A: diaphyseal periosteum from the juvenile group; B: diaphyseal periosteum from the 
mature group; C: diaphyseal periosteum from the aged group; D: metaphyseal 
periosteum from the juvenile group; E: metaphyseal periosteum from the mature 
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group; D: metaphyseal periosteum from the aged group; (In pictures, B: bone tissue; P: 
periosteum) 
 
F4/80 expression in periosteum 
The normalized F4/80+ cell number was used for this analysis. Periosteal sites and age 
were both significant (p<0.001) factors in the model as well as their interactions. The 
juvenile rats had significantly more F4/80+ cells in both layers of the diaphyseal 
periosteum compared with the mature and aged groups (p<0.001) (Fig. 3). Nearly no 
F4/80+ cells were detected in the diaphyseal periosteum in the mature and aged 
groups (Fig. 3).  
In the metaphyseal area, the F4/80+ cells were found mostly in the cambial and 
fibrous layers of aged periosteum as well as in the cambial layer of juvenile 
periosteum. Significantly fewer positive cells were identified in the mature 
periosteum (p<0.001) (Fig. 3).  
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Figure 3. Diagram and pictures (×400) of F4/80+ cell distribution in different 
periosteal areas and age groups. The juvenile rats had much more F4/80+ cells in 
cambial layer of diaphyseal periosteum (Dia-c) compared with fibrous layer (Dia-f) 
and the other two groups. In metaphyseal area, the F4/80+ cell number in both layers 
(Meta-c and Meta-f) from aged rats were more than other aged groups.  *: p<0.05. J: 
Juvenile; M: Mature; A: Aged. 
A: diaphyseal periosteum from the juvenile group; B: diaphyseal periosteum from the 
mature group; C: diaphyseal periosteum from the aged group; D: metaphyseal 
periosteum from the juvenile group; E: metaphyseal periosteum from the mature 
group; D: metaphyseal periosteum from the aged group; (In pictures, B: bone tissue; P: 
periosteum) 
 
TRAP expression in periosteum 
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The normalized TRAP+ cell number was used for this analysis. Site and age (both 
p<0.001) were significant factors in the model as well as the interaction between 
site/age (p<0.001). TRAP+ cells were mostly detected in the both layers of the 
metaphyseal area in aged rats compared with the juvenile and mature rats (p<0.001) 
(Fig.4). Very few TRAP+ cells were identified in diaphyseal periostum, although the 
cambial layer in the diaphyseal periosteum of aged rats had more positive cells than 
both the juvenile and mature aged groups (p=0.004) (Fig. 4). No difference was 
observed in the fibrous layer of diaphyseal periosteum in three age groups (p=0.147) 
(Fig. 4).  
 
Fig.4 Diagram and pictures (×400) of TRAP+ cell distribution in different periosteal 
areas and age groups. Few TRAP+ cells were found in the diaphyseal periostum 
(Dia-c and Dia-f) in any of the three groups. In the metaphyseal area, the aged rats 
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had much more TRAP+ cells in the cambial layer (Meta-c) than the fibrous layer 
(Meta-f) and the other two groups. *: p<0.05. J: Juvenile; M: Mature; A: Aged. 
A: diaphyseal periosteum from the juvenile group; B: diaphyseal periosteum from the 
mature group; C: diaphyseal periosteum from the aged group; D: metaphyseal 
periosteum from the juvenile group; E: metaphyseal periosteum from the mature 
group; D: metaphyseal periosteum from the aged group; (In pictures, B: bone tissue; P: 
periosteum) 
 
vWF expression in periosteum 
The normalized vessel number was used in the analysis. Site and age (both p<0.001) 
were significant factors for vWF expression with the interaction of site/age also being 
significant (p<0.001). Blood vessels identified by the vWF staining in diaphyseal 
periosteum revealed that juvenile rats had a higher degree of vascularization in the 
cambial layer than the older age groups (p<0.001) with the exception of the fibrous 
layer (p=0.77)(Fig.5)..  
In metaphyseal areas the juvenile and aged rats had the higher degree of 
vascularization in the cambial layer compared to the mature group (p<0.001) (Fig.5).. 
The degree of vascularization in the cambial layer of aged rats was also higher than 
the fibrous layer (p<0.001). The vessel number in the fibrous layer of mature rats was 
similar to that of juvenile rats (p=0.154), but greater than that of aged rats 
(p<0.05)(Fig.5).   
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Fig.5 Diagram and pictures (×400) of vWF+ blood vessel distribution in different 
periosteal areas and age groups. Juvenile rats had higher degree of vascularization in 
the cambial layer of diaphyseal periosteum (Dia-c) than the other two groups except 
in the fibrous layer (Dia-f). In metaphyseal area, the rats from aged group had highest 
degree of vascularization in cambial layer (Meta-c) among all three groups. The 
degree of vascularization in the cambial layer of aged rats was higher than the fibrous 
layer (Meta-f). The vessel number in the fibrous layer of mature rats was similar to 
that of juvenile rats, but more than that of aged rats.   *: p<0.05. J: Juvenile; M: 
Mature; A: Aged. 
A: diaphyseal periosteum from the juvenile group; B: diaphyseal periosteum from the 
mature group; C: diaphyseal periosteum from the aged group; D: metaphyseal 
periosteum from the juvenile group; E: metaphyseal periosteum from the mature 
 54
group; D: metaphyseal periosteum from the aged group; (In pictures, B: bone tissue; P: 
periosteum) 
 
Discussion 
The indispensable role of periosteum in both bone formation and fracture healing is 
well documented. When the periosteum is stripped off, the healing of bone defects 
and surrounding soft tissues is seriously compromised [20, 140]. This phenomenon 
has inspired many studies to focus on the application of periosteal grafts in bone and 
cartilage regeneration. It is known that periosteum is a thin membrane-like connective 
tissue covering the external surfaces of most bones and several studies have revealed 
the general histological and ultrastructural structures of periosteum from various 
bones [11, 141]. However, the detailed cellular structure of periosteum and its site 
specificity in relation to ageing are not well understood. In this study, the age-related 
degeneration (shown as decrease in thickness and cell number) was observed in the 
diaphyseal periosteum, especially the decrease in cell numbers in both cambial and 
fibrous layers in the aged group. However, in the metaphyseal areas, it is worth noting 
that the aged rats had thicker and more cellular cambial layer than the rats from the 
mature group although they were similar in the fibrous layer. There was also a 
noticeable change in cell populations within these areas, in particular an increased 
fractional number of osteoclasts. These observations would indicate aged-associated 
resorptive activity of cortical bone in metaphyseal areas, which in turn may have 
clinical relevance with more fractures reported in metaphyseal areas compared with 
diaphyseal areas in the elderly.  In a recent study by Bliziotes M. et al.,[21] an 
increase in osteoclast numbers and eroded cortical bone surfaces was found more 
obvious at the femoral neck of nonhuman primates than at the shaft, especially in the 
castrated female animals. The nature of the regulation of periosteal bone turnover 
activity is not clear, but mechanical force and sex hormones are important modulators 
of periosteal activity. It has been found that low sex steroid levels in female animals 
are associated with an increase in periosteal resorptive activity [142] and the 
application of focal mechanical force results in an increase in local bone formation 
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[143].  
Stro-1 is thought to be a pluripotent cell marker found highly expressed on various 
stromal cells [110, 144-145]. Stro-1 positive cells are capable of differentiating into 
multiple mesenchymal cell lineages including adipocytes, osteoblasts and 
chondrocytes, as well as hematopoiesis-supportive stromal cells, [144-145]. In this 
experiment, a higher percentage of Stro-1 positive cells were found in diaphyseal and 
metaphyseal periosteum in juvenile rats indicating the high osteogenic/chondrogenic 
nature of periosteum in this stage. In mature and aged groups, Stro-1 positive cells 
were significantly decreased and the intensity of Stro-1 staining was weaker in all 
periosteal areas compared with the juvenile group. In juvenile rats, the expression of 
Stro-1 was found in periosteal cells, pre-osteoblasts, osteoblasts and early osteocytes 
embedded in osteoid. Only mature osteocytes were negative for Stro-1. The broad 
expression of Stro-1 in both layers of juvenile periosteum suggests that both cambial 
and fibrous layers may be involved in the new bone formation.     
To our knowledge no other study has documented the age-related distribution of 
monocytes/macrophages or osteoclasts in periosteum even though periosteal bone 
turnover activity and osteoclast distribution have recently been documented in the 
femoral neck in a series of adult rhesus and Japanese macaques [21]. In our study, 
periosteal monocytes/macrophages and osteoclasts were identified using F4/80 and 
TRAP as specific cell markers. F4/80 (or EMR1) is a specific monocyte/macrophage 
marker, while TRAP is mainly expressed by mature osteoclasts. Although both 
monocytes/macrophages and osteoclasts derive from the haemopoietic precursors and 
both can be multinucleate, there are still substantial differences existing between these 
two cell types [146]. The differentiation into the osteoclast lineage from haemopoietic 
precursors is found prior to macrophage commitment [147]. It has been reported that 
some growth factors produced by macrophages, such as BMP2 or TGF-β, could 
promote the osteogenesis and proliferation of osteoblasts and chondrocytes in vitro 
[148]. Macrophages can develop into osteoclasts only when certain stimuli exist, such 
as receptor activator of nuclear factor Kappa B ligand (RANKL), 
Macrophage-Colony Stimulating Factor (M-CSF) or inflammation factors [149]. In 
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this study numerous macrophages, but limited number of osteoclasts, were found in 
the diaphyseal and metaphyseal periosteum especially in the cambial layer of juvenile 
rats. In aged rats both macrophages and osteoclasts were increased in the metaphyseal 
area. Few macrophages and osteoclasts were found in mature rats and the diaphyseal 
periosteum of aged rats.  
Blood vessels, identified by vWF staining, showed that both cambial and fibrous 
layers in different periosteal areas in juvenile rats were well vascularized while 
mature rats had blood vessels predominantly in the fibrous layer. In the juvenile rats 
more active periosteal osteogenic activity was found in both periosteal areas, which 
was demonstrated by increased cell numbers of mesenchymal stem cells and 
macrophages as well as increased thickness of the cambial layer. The high degree of 
vascularization in the periosteum of juvenile rats suggests a role in nutrient and 
osteoprogenitor cell supply. In diaphyseal periosteum, blood vessel numbers in the 
cambial layer decreased with age. However, in the metaphyseal region, the aged rats 
had more blood vessels in the cambial layer when compared to the juvenile and 
mature groups. The increase of periosteal vascularisation in aged rats could be related 
to increased bone resorptive activity. The increased number of blood vessels in the 
areas of osteoclastic bone resorption is also reported in bone metastasis [150] and 
ectopic bone resorption [151].  In bone development angiogenesis and bone 
resorption are closely associated with each other. Vascular endothelial growth factor 
(VEGF), the most critical growth factor for angiogenesis, has been found to stimulate 
osteoclast activity [152]. Therefore, osteoclast activity and angiogenesis can be 
regulated by the common mediators such as VEGF. 
Based on the results obtained in this study, it could be concluded that the age-related 
periosteal structure and cell populations are site-specific. The diaphyseal periosteum 
showed age-related degeneration, whereas, the metaphyseal periosteum is more 
destructive in older age. Macrophages in the periosteum may play a dual, age 
dependent role in bone metabolism with osteogenesis in young rats and 
osteoclastogenesis in aged rats. 
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Abstract 
Despite the important physiological role of periosteum in the pathogenesis and 
treatment of osteoporosis, little is known about the structural and cellular 
characteristics of periosteum in osteoporosis.  To study the structural and cellular 
differences in both diaphyseal and metaphyseal periosteum of osteoporotic rats, 
samples from the right femur of osteoporotic and normal female Lewis rats were 
collected and tissue sections were stained with hematoxylin and eosin, antibodies or 
staining kit against tartrate resistant acid phosphatase (TRAP), alkaline phosphatase 
(ALP), vascular endothelial growth factor (VEGF), von Willebrand (vWF), tyrosine 
hydroxylase (TH) and calcitonin gene-related peptide (CGRP).  The results showed 
that the osteoporotic rats had much thicker and more cellular cambial layer of 
metaphyseal periosteum compared with other periosteal areas and normal rats 
(p<0.001).  The number of TRAP+ osteoclasts in bone resorption pits, VEGF+ cells 
and the degree of vascularization were found to be greater in the cambial layer of 
metaphyseal periosteum of osteoporotic rats (p<0.05), while no significant difference 
was detected in the number of ALP+ cells between the two groups.  Sympathetic 
nerve fibers identified by TH staining were predominantly located in the cambial 
layer of metaphyseal periosteum of osteoporotic rats.  No obvious difference in the 
expression of CGRP between the two groups was found. In conclusion, periosteum 
may play an important role in the cortical bone resorption in osteoporotic rats and this 
pathological process may be regulated by the sympathetic nervous system.  
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Introduction 
The mineralization and development of bone tissue is a dynamic process determined 
by the balance between the bone formation and resorption occurring on periosteal and 
endosteal surfaces [153-155].  This modeling and remodeling process will alter the 
size, shape, internal structure, total mass, and finally the mechanical strength of bone.  
The thickness of cortical bone, a crucial feature in determining bending strength of 
bone, is defined both by periosteal and endosteal bone apposition and resorption.  
Osteoporosis is a metabolic disorder of the bone whereby the balance between bone 
formation and resorption has shifted such that the rate of bone resorption exceeds 
bone formation, resulting in net bone loss, trabecular and cortical thinning and 
porosity [156].   
Periosteum is a dense connective tissue membrane covering the outer surface of all 
bones, except at the joint of long bones.  In both normal and pathological processes 
the periosteum plays a pivotal role in both bone formation and fracture healing, in 
conjunction with the involvement of other important factors such as growth factors 
and mechanical loading [9, 20, 35].  Periosteum is a highly vascularized tissue which 
contains both osteogenic and chondrogenic progenitor cells, as well as other related 
bioactive factors [9, 14, 23].  The osteogenic function of periosteum determines the 
amount of de novo postnatal periosteal bone formation defining the thickness and 
strength of cortical bone.  Previous researchers have revealed an age related 
structural and cellular degeneration in periosteum [11, 19, 136-138].  However, in 
osteoporosis, which is characterized by decreased bone strength and a high incidence 
of fractures, the changes occurring in the periosteum are not well characterized and 
require further investigation.  Although estrogen deficiency is believed to be an 
intrinsic cause of osteoporosis, the process and mechanism of bone loss in 
osteoporosis remain unclear.  Most researchers have emphasized the bone resorption 
activity occurring in the endocortical or intramedullary area, but there are no reports 
in the current literature describing the structural and cellular changes in periosteum of 
osteoporosis.  The purpose of this study is therefore to characterize the structural and 
cellular differences in both diaphyseal and metaphyseal periosteum of osteoporotic 
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rats. 
 
Materials and Methods 
Animal samples and slices 
This study was carried out in accordance with the guidelines of the University Animal 
Ethics Committee.  Osteoporosis was induced by ovariectomy of three-month old 
female Lewis rats, followed by a 30% caloric reduced diet and four months to develop 
osteoporosis [19, 157]. The induced osteoporosis has been confirmed in our previous 
study [154]. Four osteoporotic rats and three normal female Lewis rats 
(sham-operated group in which ovaries were exposed but only equal volumes of fat 
tissue was excised), all in 7-months old, were utilized in this experiment. The right 
tibia and femur were retrieved for the following experiments. Tibia were scanned 
using a Micro CT machine (µCT 40, SCANCO Medical AG, Brüttisellen, Switzerland) 
to confirm the osteoporosis induced in rats. Then both tibia and femur were fixed in 
4% paraformaldehyde for 12 hours at room temperature, then decalcified in 10% 
EDTA and embedded in paraffin. Serial sections of sagittal slices, 5 µm thick, were 
cut from the paraffin blocks with a microtome (Leica Microsystems GmbH, 
Germany).  Only slices near the central sagittal plane were used for subsequent 
experiments.  
 
Structural observation  
After Micro CT scanning, the three dimensional (3D) image of trabecular bone in 
proximal end of tibia from both normal and osteoporotic rats was reconstructed and 
related histomorphometrical parameters, such as normalized trabecular bone volume 
(BV/TV), trabecular bone thickness (Tb.Th), trabecular bone separation (Tb.Sp),  
trabecular bone number (Tb.N) and conectivity density (Conn.D), were calculated by 
the software package of the Micro CT machine. These images and parameters were 
compared between two groups to confirm the osteoporosis induced in rats. On the 
other hand, slices from tibia were stained with hematoxylin and eosin (H&E) (HD 
Scientific Supplies, Australia), and the trabecular bones in proximal end were 
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observed under a microscope (Carl Zeiss Microimaging GmbH, Germany) to further 
confirm the induced osteoporosis.  
For periosteum observation, 1 mm lengths of periosteum from diaphyseal area and 
1mm lengths of periosteum from proximal metaphyseal area were selected for 
analysis (Fig. 1). According to the difference of cell and fiber distribution in the 
periosteum, the cambial and fibrous layers were defined [59]. The thickness of fibrous 
and cambial layers on the middle line perpendicular to the periosteum surface in each 
microscopic field, as well as the cell number of each layer throughout each periosteal 
area, were measured using Axion software (Carl Zeiss) under a microscope (Carl 
Zeiss).  Data from each animal of the osteoporotic and normal groups were recorded 
for further analysis. 
 
Figure 1: Illustration of the periosteal sites observed in this study 
 
Immunohistochemistry  
Osteoclasts were identified using a TRAP (tartrate-resistant acid phosphatase) staining 
kit (Sigma-Aldrich, Australia); ALP (Alkaline Phosphatase) specific antibody (Goat 
anti-mouse, Sigma-Aldrich, Australia) was used to identify osteogenic cells; VEGF 
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specific antibody (mouse anti-human, R&D System, Inc., USA) was used to identify 
VEGF positive cells; vWF specific antibody (mouse anti-human, Chemicom 
International Inc., USA) was used to identify blood vessels; TH (Tyrosine 
Hydroxylase) specific antibody (Rabbit anti-rat, Serotec, UK) was used to identify 
sympathetic nerve fibers; and CGRP (Calcitonin gene-related peptide) specific 
antibody (Goat anti-rat, Serotec, UK) was used to identify sensory nerve fibers.  To 
validate the results, each experiment was repeated at least three times. 
Prior to immunoperoxidase staining, endogenous peroxidase activity was quenched by 
incubating the tissue sections in 3% H2O2 for 20 minutes.  All sections were blocked 
with 10% swine serum for 1 hr.  The enzymatic treatment was used to expose 
epitopes by incubating the slices with proteinase K (DakoCytomation, USA,) for 10 
minutes at room temperature.  Sections were incubated with optimal dilution of 
primary antibody ALP (1:300), VEGF (1:300), vWF (1:500), TH (1:400) and CGRP 
(1:500) at 4oC overnight, and the following day incubated for 15 minutes with a 
biotinylated swine-anti-mouse, rabbit, goat secondary antibody (DAKO Multilink, 
USA), followed by 15 minutes incubation with horseradish perioxidase-conjugated 
avidin-biotin complex (ABC).  Antibody complexes were visualized after the 
addition of a buffered diaminobenzidine (DAB) substrate for 4 minutes; the reaction 
stopped by immersing and rinsing of sections in PBS.  Sections were then lightly 
counterstained with Mayer’s haematoxylin and Scott’s Blue for 40 seconds each, in 
between 3 minute rinses with running tap water.  Following this, the sections were 
dehydrated with ascending concentrations of ethanol solutions, cleared with xylene 
and mounted with a cover slip using DePeX mounting medium (BDH Laboratory 
Supplies, UK). Standard TRAP staining procedure was done according to the 
manufacturer’s instructions. Controls for the immunohistochemical staining 
procedures included conditions in which (a) the primary antibody was omitted for 
staining procedure, and (b) an irrelevant antibody (IgG), not present in the test 
sections, was utilized. 
At ×200 magnification and with the aid of the AxioVision software, the number of 
positive cells from each cell population in each periosteal area was counted.  Three 
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different slices from each rat from the two groups were observed and the data 
recorded for subsequent analysis. The number of active TRAP+ osteoclasts in bone 
resorption pits, ALP+ and VEGF+ cells were normalized against the total cell number 
and expressed as positive cell number per total of 100 cells from each sample in order 
to counter the effect that variations of total cell numbers from the two groups had on 
the positive cell counts.  The blood vessel counts were normalized to the vessel 
number in a 0.03mm2 periosteal area.  As for nerve staining, spatial distribution was 
observed and described. 
 
Statistical analysis 
The data from both normal and osteoporotic groups were compared using the 
Student’s t-test.  The data from different periosteum layers and periosteal areas of 
osteoporotic rats were subjected to one-way ANOVA and SNK tests and results were 
regarded as significance at p≤0.05.  Data analysis was performed using the SPSS 
software (SPSS Inc, USA).  
 
Results 
Structural differences between osteoporotic and normal rats 
Osteoporotic rat model was further confirmed by the significantly lower trabecular 
bone volume, thickness, number, connectivity density and higher trabecular bone   
separation when compared with normal rats (p<0.05)(Table 1, Fig. 2).  Typical 
fenestrated trabeculae were demonstrated in the osteoporotic rat model (Fig. 2).  
No statistically significant difference was found in the thickness and cell numbers 
between osteoporotic and normal rats of the diaphyseal periosteum, except for the 
thickness of the fibrous layer (p<0.05)(Fig. 3).  In the metaphyseal periosteum, 
osteoporotic rats had thicker and more cellular cambial layers compared with normal 
rats (p<0.001) (Fig. 3).  Although there was no significant difference in the thickness 
of the fibrous layer (p>0.05), the number of cells in the fibrous layer of osteoporotic 
rats in the metaphyseal area was higher than normal rats (p<0.001).  In osteoporotic 
rats the metaphyseal periosteum was significantly thicker and more cellular than in 
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the diaphyseal periosteum, especially the cambial layer of metaphyseal periosteum 
(p<0.05) (Fig. 3). 
 
 
 
Table 1 Histomorphometrical comparison of the tibia bone 
from osteoporotic and normal rats 
 
*: p<0.05. 
 
 
 
Figure 2: Histological validation of animal models  
Osteoporotic rat model was confirmed by the significantly loss of trabecular bones (B) 
 
BV/TV (%, 
x ±SD) 
Tb.Th(mm, x 
±SD) 
Tb.Sp(mm, x 
±SD) 
Tb.N 
(1/mm, x 
±SD) 
Conn.D(1/mm3) 
(x ±SD) 
Osteoporotic* 6.24±0.2 0.07±0.02 1.36±0.16 0.78±0.08 15.85±0.51 
Normal 20.5±1.4 0.1±0.02 0.3±0.05 3.11±0.35 51.02±10.49 
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compared with normal rats (A) in 3D reconstructed images; Typical fenestrated 
trabeculae were demonstrated in the osteoporotic rat model (D) in contrast to normal 
rats (C). H&E staining pictures (C&D) were taken at 40 × magnification. 
 
 
 
 
Figure 3: Diagrams and H&E staining (200) of diaphyseal and metaphyseal 
periosteum from normal and osteoporotic rats. (A) diaphyseal periosteum from 
normal rats; (B) diaphyseal periosteum from osteoporotic rats; (C) metaphyseal 
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periosteum from normal rats; (D) metaphyseal periosteum from osteoporotic rats. 
(NO: normal rats; OP: osteoporotic rats; Dia-c: cambial layer of diaphyseal 
periosteum; Dia-f: fibrous layer of diaphyseal periosteum; Meta-c: cambial layer of 
metaphyseal periosteum; Meta-f: fibrous layer of metaphyseal periosteum;  : p<0.05. 
In pictures: B: bone tissue; P: periosteum; C: cambial layer; F: fibrous layer.) 
 
TRAP+ osteoclasts in periosteum 
The normalized cell number of active TRAP+ osteoclast in bone resorption pits from 
the cambial layer was used for this analysis. The osteoporotic rats had significantly 
more active TRAP+ osteoclasts in both diaphyseal and metaphyseal periosteal areas 
(p<0.001) compared to normal rats (Fig.4 & 5).  In osteoporotic rats, the cambial 
layer of metaphyseal periosteum had similar TRAP+ osteoclast density in bone 
resorption pits when compared with the cambial layer of diaphyseal periosteum 
(p>0.05) (Fig.4). 
 
ALP expression in periosteum 
The normalized ALP+ cell count was used for this analysis.  No significant 
difference was found in the ALP expression in either diaphyseal and metaphyseal 
periosteum of osteoporotic rats compared to normal rats (p>0.05) (Fig.4 & 5).  No 
difference was detected between the cambial and fibrous layers in diaphyseal and 
metaphyseal periosteum respectively.  Nor was there any significant difference to the 
ALP expression between different periosteal sites in osteoporotic rats (p>0.05) 
(Fig.4). 
 
VEGF expression in periosteum 
The normalized VEGF+ cell count was used for this analysis.  Significantly more 
VEGF+ cells were found in the cambial layer of the metaphyseal periosteum of 
osteoporotic rats compared to normal rats (p<0.001) (Fig.4 & 5).  No significant 
difference was found in other periosteal areas.  In osteoporotic rats the cambial layer 
of both the metaphyseal and diaphyseal periosteum had more VEGF positive cells 
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than the fibrous layers in both periosteal areas, whilst the number of VEGF positive 
cells in the cambial layer of metaphyseal periosteum was higher than that in the 
cambial layer of diaphyseal periosteum (p<0.001) (Fig.4). 
 
Blood vessels revealed by vWF  
The normalized blood vessel count was used for this analysis.  Osteoporotic rats had 
higher degree of vascularization in the cambial layers of both the diaphyseal and 
metaphyseal periosteum compared to normal rats (p<0.001), especially in the 
metaphyseal periosteum (Fig.4 & 5).  No significant difference was found in the 
fibrous layer of either periosteal area between the two groups.  In osteoporotic rats, 
the cambial layer of metaphyseal periosteum had a higher degree of vascularization 
than the fibrous layer (p<0.001) (Fig.4 & 5). 
 
Sympathetic nerves revealed by TH 
TH staining revealed that the distribution of sympathetic nerve fibers was mainly 
present in osteoporotic rats, predominantly in the cambial layer of periosteum (Fig. 5).  
A slight TH stain was observed in the cambial layer of metaphyseal area of normal rat.  
No obvious staining was detected in the fibrous layer or diaphyseal area.  
 
Sensory nerves revealed by CGRP 
Sensory nerve fibers identified by CGRP antibodies were found in both osteoporotic 
and normal rats (Fig. 5).  There was no discernible difference in the expression of 
CGRP between the two groups in the different periosteal areas.  However, in normal 
rats CGRP+ nerve fibers appeared to be distributed in both fibrous and cambial layers, 
whereas in osteoporotic rats most CGFP+ nerve fibers were present in the cambial 
layer of the metaphyseal area.  
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Figure 4: Cellular differences in diaphyseal and metaphyseal periosteum between 
osteoporotic and normal rats. (NO: normal rats; OP: osteoporotic rats; Dia-c: cambial 
layer of diaphyseal periosteum; Dia-f: fibrous layer of diaphyseal periosteum; Meta-c: 
cambial layer of metaphyseal periosteum; Meta-f: fibrous layer of metaphyseal 
periosteum; :p<0.05) 
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Figure 5: Immunohistochemical staining (200) of metaphyseal periosteum from 
normal and osteoporotic rats. (NO: normal rats; OP: osteoporotic rats; B: bone tissue; 
P: periosteum)  
 
Discussion 
Osteoporosis is characterized by a negative balance of bone metabolism which leads 
to a decreased bone mass with subsequent thinning of the trabecular and cortical bone 
and a significantly greater risk of bone fractures.  The cortical bone expansion 
through the periosteum is the most effective way to increase bone strength and protect 
against fractures. Despite the synergistical role and potential significance of 
periosteum in the pathogenesis and treatment of osteoporosis, little is known about 
this role of the periosteum in osteoporosis.  Knowledge of periosteal structural and 
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cellular characteristics would greatly enhance our understanding of the disorder and 
aid in the development of more specific and effective treatments. 
Osteoporosis patients are at a greater risk of bone fractures, and these fractures have 
different patterns compared with those in patients without osteoporosis [158].  Most 
fall related fractures in osteoporotic and elderly patients begin in the cortex of the 
metaphyses or former epiphyses, intertrochanteric, and femoral neck cortices; they 
never begin in metaphyseal spongiosa and rarely in the diaphyseal cortex [158].  
This phenomenon indicates a fundamental difference in the mechanical environment 
and bone strength along the bone axis. It is known that endosteal or intramedullary 
bone resorption activity is greater in osteoporotic bone compared to normal bone, 
which is thought to be the main cause of net bone loss [159].  However, the synergic 
role of the periosteum in osteoporosis is not well understood.  In an attempt to 
further the understanding of the function of periosteum at different periosteal sites in 
osteoporosis, we investigated the basic structure and related cell populations in the 
diaphyseal and metaphyseal periosteum of osteoporotic rats. 
In the general H&E stain and histomorphometry observations, the thickness and cell 
numbers in the cambial layer of metaphyseal periosteum from osteoporotic rats were 
found to be much greater compared to normal rats, despite both groups being of 
similar age (7 months).  This structural difference appears to be closely related to the 
different cell populations found in the two cohorts, an observation confirmed by the 
immunohistochemical staining.  
To our knowledge, no previous studies have documented the distribution of active 
osteoclasts in the periosteum covering osteoporotic bones, although periosteal bone 
turnover activity and osteoclast distribution have recently been documented in the 
femoral neck in a number of adult rhesus and Japanese macaques [21].  In our study, 
periosteal osteoclasts were identified using TRAP specific cell markers.  
Immunohistochemical observations in this study found the evidence of a noticeable 
increased fraction of active osteoclasts in the cambial layer of both diaphyseal and 
metaphyseal periostea from osteoporotic rats.  As these observed osteoclasts were 
found in bone resorption pits on eroded bone surfaces, which means they are active 
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osteoclasts, it might suggest more serious bone resorption activities on both 
diaphyseal and metaphyseal cortical bone surfaces of osteoporotic rats compared to 
the normal rats.  As the thickness of cortical bone in metaphyseal area is thinner than 
the diaphyseal area [160], the metaphyseal bone could be more susceptible of bone 
fractures than the diaphyseal in osteoporosis conditions. This phenomenon could 
potentially have clinical relevance as more fractures are reported in the metaphyseal 
areas compared to the diaphyseal areas in osteoporotic patients [158]. Age-related 
bone loss often shows the following morphological changes including decreased 
periosteal apposition, endosteal bone loss, bone loss on the trabecular, endocortical 
and intracortical surfaces, although some controversies have been reported on 
periosteal apposition, which shows that periosteal apposition continues, even after 
menopause, and may partly offset the bone resorption on the endosteal surface [142].  
However, the findings in our study suggest that bone resorption activity in the 
periosteum is greater in osteoporotic rats compared to normal rats and that the 
behavior of the osteoclast cells is destructive.  On the other hand, osteogenic activity 
demonstrated by the ALP expression in this experiment revealed no significant 
difference was detected in either the different periosteal sites of osteoporotic rats or 
between the two groups of rats.  Given the increased number of active osteoclasts in 
the periosteum of osteoporotic rats, the relatively stable osteogenic activity might 
therefore be inadequate to offset the bone resorption, which would consequently incur 
the net bone loss and strength decrease. This failed adaptation of bone to the bone 
resorption could be the result of the estrogen withdrawal in the osteoporotic rats since 
the estrogen is believed to be able to preserve the bone mass and decrease the bone 
resorption activity [161-162]. According to these findings, periosteum seems playing 
more destructive roles in osteoporosis, and new periosteum-targeting medicines or 
operations could be developed to suppress the bone resorption and enhance the 
osteogenic activities in periosteum, especially in metaphyseal area.  
VEGF is an important growth factor which is reported to be involved in angiogenic, 
osteogenic and osteoclastogenic processes [152, 163-164].  Bone development, 
angiogenesis, bone formation and bone resorption are all closely associated processes 
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with VEGF known to stimulate osteoclast activity [152, 163-164].  Osteoclast 
activity and angiogenesis may therefore be regulated by a common mediator such as 
VEGF.  The data in our study seems to support this view since a higher expression of 
VEGF, as well as more vWF+ blood vessels, was found in the vicinity of active 
TRAP+ osteoclasts in osteoporotic rats compared to normal rats.  The increase of 
VEGF expression and periosteal vascularization in the periosteum of the osteoporotic 
rats may be related to the increased bone resorptive activity in these periosteal areas.   
The reason for the increased expression of sympathetic nerve fibers in the periosteum 
in osteoporosis is unclear, although it is well documented that sympathetic nerve 
fibers are present in both the periosteum and bone [25-26].  Sympathetic innervation 
of periosteum and bone contributes to the regulation of bone cell activity and, 
therefore, the eqiulibrium between bone modeling and remodeling [27].  It is known 
that surgical and chemical sympathectomy can both modulate bone cell function.  
However, the sympathetic nervous system (SNS) can give rise to both anabolic and 
catabolic effects [28-31] and its role in regulating bone remodeling is, therefore, 
controversial.  In this study, the distribution of sympathetic nerve fibers was 
demonstrated by employing an antibody against an SNS specific marker, tyrosine 
hydroxylase, which is expressed in adrenergic fibers.  More sympathetic nerve fibers 
were found in the cambial layer of periosteum of osteoporotic rats compared to 
normal rats and this finding was also in accordance with the distribution of TRAP+, 
ALP+, VEGF+ cells and blood vessels. The co-existence of nerve fibers and various 
cell populations indicates that sympathetic nerves in the periosteum are involved in 
the pathogenesis of osteoporosis by interacting with, and possibly regulating, 
osteogenic, osteoclastogenic and angiogenic factors.  Sensory nerve fibers identified 
by CGRP antibody were found similarly expressed in both osteoporotic and normal 
rats, although the distribution is slightly different between the two groups.  It is 
generally accepted that CGRP can promote osteogenesis and decrease bone resorption 
[32, 165]. CGRP has also been shown to inhibit osteoclastic resorption like calcitonin 
[165].  The similar expression of CGRP in both osteoporotic and normal rats 
suggests a similar osteogenesis-related role for CGRP in the two groups.   
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Based on the findings from this study, it could be concluded that the periosteum of 
osteoporotic rats differs from normal rats both in terms of structure and cell 
populations. This is especially evident in the cambial layer of metaphyseal periosteum.  
Bone resorption appears to be more active in the periosteum of osteoporotic rats 
compared to normal rats, whereas bone formation activity is comparable between the 
two groups.  The dysregulation of bone resorption and formation in the periosteum, 
characteristic of the pathogenesis of osteoporosis, may therefore be the effect of the 
interaction between various neural pathways and the cell populations residing within 
it. The findings of this study were observed from rat osteoporosis model. It is known 
that there are some differences between human and rat in bone remodelling and 
fragility due to the differences in bone biology and physiology, therefore, these 
findings need to be further validated in mammal models to be relevant to human 
osteoporosis.  
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Abstract 
Angiogenesis is a well balanced process controlled by pro- and anti-angiogenic 
factors. Vascular endothelial growth factor (VEGF) is a major pro-angiogenic factor, 
while pigment epithelial-derived factor (PEDF) is the most potent natural 
angiogenesis inhibitor. In this study, BMSCs were isolated and cultured in angiogenic 
media containing 20ng, 40ng and 80ng/ml VEGF. The alterations of VEGF/PEDF 
expression pattern and endothelial cell differentiation of BMSCs were assessed. 
BMSCs cultured under cobalt chloride (CoCl2)-induced hypoxia conditions with 
normal or angiogenic media were also investigated. To further test the ability of 
BMSC to induce vascularization in vivo, the treated cells were injected 
subcutaneously into SCID mice.  Results showed that PEDF was more prominently 
expressed than VEGF in BMSCs (p<0.05), which was reverse to the expression in 
HUVECs. The ratio of VEGF/PEDF in BMSCs increased when VEGF concentration 
reached 40ng/ml in the culture media, but deceased at the 80ng/ml (p<0.05). Under 
CoCl2-induced hypoxia conditions, the VEGF/PEDF ratio of BMSCs increased 
significantly in both normal and angiogenic media (p<0.05). No expression of 
endothelial cell markers was found in BMSCs cultured in either normxia or hypoxia 
conditions (p>0.05). In vitro and in vivo vascularization study showed that the 
CoCl2-treated BMSCs could stabilize and induce much higher degree of 
vascularization than BMSCs or BMSCs treated with 20ng/ml VEGF (p<0.01). These 
results indicate that BMSCs are important regulators in angiogenesis, but unable to 
differentiate into endothelial cells under angiogenic or hypoxia culture conditions.  
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Introduction  
Angiogenesis is thought to be a process balancing between pro- and anti-angiogenic 
factors. Vascular endothelial growth factor (VEGF) is one of the most important 
pro-angiogenic factor and could initiate angiogenic differentiation of various 
endothelial progenitor cells (EPCs)[119]. VEGF could be expressed by a broad range 
of cells including bone marrow mesenchymal cells (BMSCs) [166]. On the other hand, 
pigment epithelial-derived factor (PEDF) which was initially purified from the 
conditioned media of human fetal retinal pigment epithelial (RPE) cells is the most 
potent natural angiogenesis inhibitor [167]. PEDF is also considered to be the key 
factor associated with avascularity of the cornea [167]. In the vascualrization of retina, 
the balance between VEGF and PEDF expression plays a very crucial role [168]. 
Despite the importance of VEGF and PEDF expression in the process of angiogenesis, 
very few information could be found in literatures about the VEGF/PEDF expression 
pattern in BMSCs in relation to angiogenesis. Furthermore, as the BMSCs are 
believed involved in the various angiogenic environments [169], whether 
VEGF/PEDF expression pattern could be influenced by the extracellular VEGF alone 
or together with oxygen stress and whether any changes in this expression pattern 
could influence the endothelial cell differentiation of BMSCs are all questions 
needing further investigations.  
Bone marrow comprises a dual stem or progenitor cell system: the hematopoietic cell 
system and non-hematopoietic mesenchymal cell system [110-111]. When cultured in 
vitro, BMSCs rapidly adhere and can be easily separated from the non-adherent 
hematopoietic cells through repeated washing. Hematopoietic stem cells (HSCs) in 
bone marrow are the reservoir of various blood cells, such as erythrocytes, leukocytes, 
macrophages or platelets, and they also contain endothelial progenitor cells (EPCs) 
which can become mature endothelial cells when necessary [112-113]. BMSCs, when 
cultured in vitro, are negative for CD45, CD14, CD31 and CD34 but positive for 
CD105, CD 44, CD73 and CD90. They are a mixture of multipotent progenitor cells 
which can differentiate into various other mesodermal cells, such as osteoblasts, 
chondrocytes, fibroblasts or adipocytes [114]. However, whether the in vitro cultured 
 78
BMSCs could be differentiated into endothelial cells has long since been a 
controversial and unsettled question [170-171]. The information about the endothelial 
cell differentiation of BMSCs in hypoxia situations is also lacking. 
In this study, the VEGF/PEDF expression pattern of BMSCs with or without 
supplementary VEGF and the effect of the VEGF/PEDF expression pattern on the 
endothelial cell differentiation of BMSCs under normoxia and cobalt 
chloride-induced hypoxia situations were investigated. The human umbilical vein 
endothelial cells (HUVECs) were used as the positive control when necessary. 
 
Materials and methods 
Cells and cell culture 
Bone marrow was obtained from patients in orthopaedic department of Prince Charles 
Hospital with informed consent and ethics approval from the Ethics Committee of 
Queensland University of Technology. Mononuclear cells (MNCs) were isolated from 
the bone marrow by density gradient centrifugation over Lymphoprep (Axis-shield 
PoC AS, Oslo, Norway) according to the manufacturer’s protocol. The MNCs were 
plated into the culture flasks and cultured in Dulbecco’s Modified Eagle Medium 
(DMEM; Invitrogen Australia Pty Ltd., Mt Waverley, VIC, Australia) containing 10% 
(v/v) fetal calf serum (FCS; InVitro Technology, Noble Park, VIC, Australia) and 1% 
(v/v) penicillin/streptomycin (Invitrogen). The unattached hematopoietic cells were 
removed through changing media. When reaching the 70-80% confluence, the 
attached mesenchymal cells were subcultured after treatment with 0.25% trypsin 
(Invitrogen) and 1mM EDTA (Invitrogen). Only P2-P5 mesenchymal cells were used 
in this study. Human umbilical vein endothelial cells (HUVECs; Clonetics, San diego, 
CA, USA) were used as the positive control when necessary. HUVECs were cultured 
in a defined endothelial cell growth medium containing VEGF, FGF-2, IGF-1, EGF, 
ascorbic acid and hydrocortisone (EGM-2; Lonza Australia Pty Ltd., Mt Waverley, 
VIC, Australia) supplemented with 2% FCS.  The medium was changed every three 
days until the cells were confluent. 
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Endothelial cell differentiation of BMSCs under different extracellular VEGF 
concentrations 
BMSCs from five patients (one female and four male patients with the age ranging 
from 40y to 78y and averaging 61y) were included in this experiment. When BMSCs 
reached 80% confluence in the flask, angiogenic differentiation media with different 
VEGF (R&D Systems, Inc., Minneapolis, MN, USA) concentrations (DMEM 
supplemented with 5% FCS and 20ng, 40ng and 80ng VEGF per ml respectively) 
were added and changed every three days. After 6 days culturing, real time 
q-Polymerase Chain Reaction (real-time q-PCR), western blot, immunohistochemical 
staining and flow cytometry were conducted on these BMSCs. The ability to form 
vessel-like structures in vitro of these BMSCs was tested on Matrigel.  
 
Endothelial cell differentiation of BMSCs under cobalt chloride-induced hypoxia  
BMSCs from six patients (two female and four male patients with the age ranging 
from 47y to 76y and averaging 57y) were included in this experiment. When BMSCs 
reached 80% confluence in the flask, they were subcultured and equally allocated into 
following three groups: BMSCs cultured in normal DMEM containing 5% FCS; 
BMSCs cultured in DMEM containing 5% FCS and 100µM cobalt chloride; BMSCs 
cultured in DMEM containing 5% FCS, 100µM cobalt chloride and 20ng VEGF/ml. 
The media in each group were changed every three days and on the day 6, real-time 
q-PCR, western blot, immunohistochemical staining and flow cytometry were 
conducted on these BMSCs. The ability to form vessel-like structures in vitro of these 
BMSCs was tested on Matrigel.  
    
Real time q-Polymerase chain reaction 
On the day 6 of culturing, total RNA and cDNA of HUVECs and BMSCs cultured 
under different conditions were obtained using a cDNA reverse transcription kit 
(Invitrogen). The total cDNA were used to do the real time q-PCR. Briefly, a 12.5µl 
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SYBR green q-PCR master mix (AB Applied Biosystems, Melbourne, Australia) was 
mixed with 5 µl Ultrapure water (Invitrogen), 2.5 µl reverse and forward primers 
(Sigma-Aldrich Pty. Ltd, Castle Hill, NSW, Australia) and 2.5 µl cDNA to make a 25 
µl final reaction system in a 96-well PCR clear plate. The gene expressions of PEDF, 
VEGF, CD31, VEGF receptor 2 (VEGFR2), von Willebrand factor (vWF), 
endothelium nitric oxide synthases (eNOS) were detected. The 18s gene was used as 
the house keeping gene. The sequences of forward and reverse primers of each gene 
observed are detailed in Table 1. Each sample was added in plates in triplicate and the 
PCR was run on a q-PCR machine (7300 sequence detection system, AB Applied 
Biosystems, Melbourne, Australia) according to the manufacturer’s instruction.  The 
final results came out as average cycle numbers (Cts) which was normalized against 
Cts of 18s by subtraction. The final relative expression of each target gene was 
calculated using the following formula: 2 -(normalized average Cts) × 104.  
 
Table 1 Primer sequences for the gene observed in this study 
genes Primer seqences Gene bank No. 
PEDF For.TTCAAAGTCCCCGTGAACAAG AF400442 
 Rev.GGATCGCACCCGGTACAG  
VEGF For.5’GCTGTCTTGGGTGCATTGG E14233 
 Rev.5’GCAGCCTGGGACCACTTG  
VEGFR2 For.5’CAAACGCTGACATGTACGGTCTA AF063658 
 Rev.5’CCAACTGCCAATACCAGTGGAT  
CD31 For. 5’ TGGAGCACAGTGGCAACTACAC M37780 
 Rev.5’CCACGATGCTGCTGACCTT  
vWF For.5’AGCCCCACCACTCTGTATGTG NM_000552 
 Rev.GTAGCCTGCTGCAGTAGAAATCG  
eNOS For.5’CGGCATCACCAGGAAGAAGA AF400594 
 Rev.5’CATGAGCGAGGCGGAGAT  
18s For.5’TTCGGAACTGAGGCCATGAT M10098 
 Rev.5’CGAACCTCCGACTTCGTTC  
 
Western blot 
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On the day 6 of culturing, total cell proteins were obtained using a cell lysis buffer 
supplemented with proteinase inhibitors (Roche Ltd., Dee Why, NSW, Australia). The 
protein concentration was determined by a BCA protein assay kit (Sigma) and 10µg 
proteins from each sample were used to do the western blot. Briefly, the protein 
samples were loaded onto SDS-page gels and run at 125V for 1h. Then the proteins 
were transferred to a nitric cellulous membrane (Pall corporation, East Hills, NY, 
USA) using semi-dry transfer method. The VEGF, PEDF and α-tubulin were 
recognized by VEGF (1:2000, rabbit anti-human, Thermo Fisher Scientific, Fremont, 
CA, USA), PEDF (1:2000, mouse anti-human Millipore, North Ryde, NSW, Australia) 
and α-tubulin (1:5000, rabbit anti-human, Abcom Inc., Cambridge, MA, USA) 
primary antibodies which then bound to the HRP-conjugated anti-mouse or rabbit 
secondary antibodies (1:105, Thermo Fisher Scientific, Fremont, CA, USA). 
Super-signal substrate (Thermo Fisher Scientific, Fremont, CA, USA) was used to 
visualize the band through eliciting green fluorescence which could leave band 
images on X-ray films. All operations were performed under the same conditions.  
 
Flow cytomytry and immunohistochemistry 
To detect endothelial cell markers, flow cytomytry and immunohistochemistry were 
performed. For the flow cytomtry, 105 cells were resuspended in 3% PBS/BSA at 4°C 
and incubated with CD31 (mouse anti-human, 1:100, Invitrogen, Mt Waverley, VIC, 
Australia) or VEGFR2 (goat anti-human, 1:100, R&D Systems, Inc., Minneapolis, 
MN, USA) primary antibody for 30mins on ice. After incubation and repeated wash 
for at least three times with 3% PBS/BSA, cells were resuspended and incubated with 
a biotinylated universal secondary antibody (swine-anti-mouse, rabbit and goat, ready 
to use, DAKO Multilink, CA, USA) for 30mins on ice. After washing away secondary 
antibody, the PE-conjugated anti-biotin antibody (1:200, Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA) was added into the cell suspension and 
incubated for another 30mins. After totally removing the antibodies by repeated 
washing, cells were resuspended in 1ml 3% PBS/BSA and read through in a flow 
cytometry machine (Becton Dickinson, Cowley, Oxford, UK). Negative controls were 
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cell suspensions incubated with mouse IgG isotype as primary antibody, and 
HUVECs were used as positive controls. For the immunohistochemistry, cells were 
cultured in chamber slices and on the day 6 of culturing, the cells were fixed in 4% 
paraformaldehyde and washed with PBS for at least three times. After cell 
permeablization by 0.1% triton solution for 6mins, endogenous peroxidase activity 
was quenched by incubating the sample slices with 3% H2O2 for 15mins and then 
blocked with 10% swine serum for 1h. The cells were incubated with the vWF 
(Rabbit anti-human, 1:300, Millipore, North Ryde, NSW, Australia) and eNOS (goat 
anti-human, 1:100, R&D Systems, Inc., Minneapolis, MN, USA) primary antibodies 
overnight at 4°C, followed by incubation with the biotinylated swine-anti-mouse, 
rabbit, goat secondary antibody (DAKO Multilink, CA, USA )for 15mins, and then 
with horseradish peroxidase-conjugated avidin-biotin complex (DAKO Multilink, CA, 
USA) for another 15mins. The antibody complexes were visualized by the addition of 
a buffered diaminobenzidine (DAB) substrate for 4 mins. Mayer’s haematoxylin (HD 
Scientific Pty Ltd., Kings Park, NSW, Australia) were used for counter staining.  
 
Matrigel Assay    
Aliquots (50µl) of growth factor-reduced phenol red free Matrigel matrix (BD 
biosciences, North Ryde, NSW, Australia) were added into individual wells of a 
96-well cell culture plates and allowed to polymerize at 37°C for at lease 30min. 3 
×103 BMSCs, HUVECs and BMSCs cultured under different conditions, i.e. with 
different VEGF concentrations or under cobalt chloride-induced hypoxyia, were 
added onto the matrigel matrix. The new vessel networks formed on the matrigel by 
different cells were observed using a microscope at 40× magnification after 6 hrs 
incubation under 37°C and 5% CO2 condition. To investigate the interaction between 
the HUVECs and BMSCs cultured under different conditions, 3 ×103 HUVECs were 
mixed with CoCl2-treated BMSCs or untreated BMSCs in serum-free DMEM at the 
ratio of 1:1, and seeded onto the Matrigel. The unmixed HUVECs and CoCl2-treated 
BMSCs were used as controls. The vessel networks formed on the matrigel by 
different cell combinations were observed after 24 hrs and 72hrs incubation. The total 
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number of vessels in five randomly selected areas from each sample was recorded 
using the Axion software (Carl Zeiss Microimaging GmbH, Göttingen, Germany). 
This experiment was repeated three times and the average was taken for statistical 
analysis. 
 
In vivo vascularization assessment  
To assess the angiogenesis of BMSCs treated in different ways, three SCID mice 
(Animal Resources Centre, Canning Vale, WA, Australia) were used with the ethics 
approval from QUT Animal Ethics Committee. The animals were anesthetized with 
1ml of Katemine (100mg/ml) and 0.15ml of xylazine (20mg/ml) injected 
intraperitoneally. 5 × 104 resuspended BMSCs, HUVECs, BMSCs treated with 
20ng/ml VEGF for 6 days, BMSCs treated with 100µM cobalt chloride for 6 days and 
BMSCs treated with both 20ng/ml VEGF and 100µM cobalt chloride for 6 days were 
mixed with matrigel at a ratio of 1:2 to a final volume of 300 µl before subcutaneous 
injection on the dorsal area of mice. Gels without cells were used as negative control. 
On each mouse, six gels, one from each group, were injected with approximate 1cm 
apart along the both sides of longitudinal middle line of dorsal area. All animals were 
sacrificed after 10 days and the implants were retrieved, photographed and fixed in 
4% para formaldehyde. After being embedded in paraffin, the implants were sliced 
and three serial sagittal slices close to the centre of each implant were used to do the 
immunohistochemical staining. To detect the endothelial cells, vWF antibody was 
used. The staining method is the same as above described. All vWF+ positive cells, 
capillaries or blood vessels were counted on each slice and normalized to the slice 
area (mm2). The average from each group was used to do the statistical analysis. To 
confirm the relationship between the VEGF expression and vascularization, the same 
VEGF antibody (1:50) for the western blot was used to stain the harvested samples by 
the same immunohistochemical method described above.   
 
Statistical analysis 
Analysis was performed using SPSS software (SPSS Inc., Chicago, Il., USA). All the 
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data were analyzed using Student-t, one-way ANOVA or Friedman test. The 
significance level was set at p ≤0.05.         
 
Results 
The original VEGF/PEDF expression pattern of BMSCs and HUVECs 
Real time q-PCR revealed that both VEGF and PEDF gene expressions of BMSCs are 
significantly higher than those of HUVECs (Student-t test, p<0.01) (Fig. 1A) and the 
VEGF/PEDF expression pattern is also very much different between these two 
different cells. BMSCs have significantly higher PEDF expression compared with the 
VEGF (Student-t test, p<0.05) (Fig. 1A), while HUVECs have much lower PEDF 
expression than the VEGF (Student-t test, p<0.05) (Fig. 1A). The average 
VEGF/PEDF expression ratio of HUVECs is around 8.0 which is significantly higher 
than that (around 0.5) of BMSCs (Student-t test, p<0.01) (Fig. 1B). The western blot 
and immunohistochemical staining on the VEGF and PEDF proteins confirmed these 
differences between the two different cells (Fig. 1C, D).   
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Figure 1. The original VEGF/PEDF expression pattern of BMSCs and HUVECs 
A. Relative gene expression of VEGF and PEDF of BMSCs and HUVECs; B. 
VEGF/PEDF expression ratio of BMSCs and HUVECs; C. Western blot showing the 
PEDF and VEGF expressions on protein level in BMSCs and HUVECs. α-tubulin 
(TUB) used as control; D. Immunohistochemical staining (400×) showing the PEDF 
and VEGF expression of BMSCs and HUVECs (a. PEDF expression of BMSCs; b. 
VEGF expression of BMSCs; c. PEDF expression of HUVECs; d. VEGF expression 
of HUVECs.). *: p<0.05; **: p<0.01. 
 
The VEGF/PEDF expression pattern and endothelail cell differentiation of 
BMSCs under different extracellular VEGF concentrations 
When cultured in angiogenic media with upgrading VEGF concentrations, BMSCs 
showed different VEGF/PEDF gene expression pattern (Fig 2). When the extracellular 
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VEGF concentration was increased from “no added VEGF” through to 40ng/ml, the 
PEDF expression decreased by almost half of the original expression, but when the 
VEGF concentration reached 80ng/ml, the PEDF expression returned to almost 75% 
of its original expression (Friedman test, p<0.05) (Fig.2 B). The VEGF expression, on 
the other hand, increased to around 1.5 times as much as the original expression at  
the 20ng/ml extracellular VEGF concentration, and then fell back to almost its 
original expression as the extracellular VEGF concentration increased from 40ng/ml 
to 80ng/ml (Friedman test, p<0.05) (Fig.2 A). The VEGF/PEDF expression ratio 
reached its peak average value of around 0.8 at the 40ng/ml extracellular VEGF 
concentration (Friedman test, p<0.05) (Fig.2 D). These changes in VEGF/PEDF 
expression pattern were confirmed by western blot on those two proteins (Fig.2 C). 
The angiogenic differentiation of BMSCs under various extracellular VEGF 
concentrations was also tested using real time-qPCR against CD31, VEGFR2, vWF 
and eNOS III endothelial cell markers. The HUVECs were used as control. HUVECs 
showed significantly higher gene expression of those markers than BMSCs cultured 
in either normal DMEM or angiogenic media with different VEGF concentrations 
(one-way ANOVA, p<0.01) (Fig.3 A), while there were no significant differences 
among different BMSCs groups (one-way ANOVA, p>0.05) (Fig.3 A). 
Flowcytometry on CD31 and VEGFR2 revealed no expression differences between 
the undifferentiated and differentiated BMSCs (Fig.3 B). There were no obvious 
immunohistochemical staining against vWF and eNOS III on different BMSCs slices 
in contrast to the HUVECs (Fig.3 C). The Matrigel assay showed HUVECs formed 
much more new vessel-like structures within 6hrs compared with both 
undifferentiated and differentiated BMSCs (one-way ANOVA, p<0.01) (Fig.6), while 
there were no difference among BMSC groups in the ability to form vessel-like 
structures (one-way ANOVA, p>0.05) (Fig.6)  
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Figure 2. The VEGF/PEDF expression pattern of BMSCs under different 
extracellular VEGF concentrations 
A. Fold change of VEGF gene expression of BMSCs cultured with different 
extracellular VEGF concentrations against BMSCs cultured in DMEM; B. Fold 
change of PEDF gene expression of BMSCs cultured in different extracellular VEGF 
concentrations against BMSCs cultured in DMEM; C. Western blot showing the 
alterations of PEDF and VEGF expression on protein level in BMSCs cultured under 
different conditions (B: BMSCs cultured in DMEM; 20ng: BMSCs cultured in 
DMEM plus 20ng/ml VEGF; 40ng: BMSCs cultured in DMEM plus 40ng/ml VEGF; 
80ng: BMSCs cultured in DMEM plus 80ng/ml VEGF). α-tubulin (TUB) used as 
control; D. The alterations of VEGF/PEDF gene expression ratio in BMSCs cultured 
under different conditions. *: p<0.05. 
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Figure 3. Endothelial cell differentiation of BMSCs under different extracellular 
VEGF concentrations 
A. Relative gene expression of endothelial cell markers in BMSCs cultured under 
different conditions and HUVECs; B. Flow cytometry graphs showing the expression 
of CD31 and VEGFR2 on HUVECs and BMSCs cultured under different conditions; 
C. Immunohistochemical staining (100×) of vWF and eNOSIII on HUVECs and 
BMSCs cultured under different conditions (a-d. vWF staining on BMSCs cultured in 
DMEM or DMEM plus 20,40 or 80ng/ml VEGF; e. vWF staining on HUVECs; f-i. 
eNOSIII staining on BMSCs cultured in DMEM or DMEM plus 20,40 or 80ng/ml 
VEGF;j. eNOSIII staining on HUVECs.). **: p<0.01. 
 
 
The VEGF/PEDF expression pattern and angiogenic differentiation of BMSCs 
 89
under hypoxia induced by cobalt chloride 
When cultured under hypoxia induced by 100µM CoCl2, BMSCs significantly 
increased the VEGF expression by almost 5 times on average and cut off the PEDF 
expression by nearly 50% (Friedman test, p<0.05) (Fig.4 A&B). The VEGF/PEDF 
expression ratio increased to about 4.0 (Fig.4 D). The addition of 20ng/ml VEGF did 
not significantly influenced the effect of CoCl2 on the VEGF/PEDF expression 
(Friedman test, p>0.05) (Fig.4 A,B&D). The endothelial cell differentiation of 
BMSCs under hypoxia situation was also investigated using real time q-PCR against 
CD31, VEGFR2, vWF and eNOS III endothelial cell markers. No significant 
differences were found in the expressions of these markers between BMSCs, BMSCs 
treated with 100µM CoCl2 alone or with both 100µM CoCl2 and 20ng/ml VEGF 
(one-way ANOVA, p>0.05) (Fig.5 A). Flowcytometry and immunohistochemical 
staining revealed no obvious expressions of those markers compared with HUVECs 
(Fig.5 B&C). Matrigel assay showed no difference in the ability to form vessel-like 
structures within 6hrs among different BMSCs groups (one-way ANOVA, p>0.05) 
(Fig.6). 
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Figure 4. The VEGF/PEDF expression pattern of BMSCs under hypoxia induced 
by cobalt chloride 
A, B&D. Bar graphs showing the relative gene expression and ratio of VEGF and 
PEDF of BMSCs cultured under different conditions; C. Western blot showing the 
alterations of PEDF and VEGF expression on protein level in BMSCs cultured under 
different conditions (B: BMSCs cultured in DMEM; BC: BMSCs cultured in DMEM 
plus 100µM CoCl2; BVC: BMSCs cultured in DMEM plus both 20ng VEGF/ml and 
100µM CoCl2.) *: p<0.05. 
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Figure 5. Endothelial cell differentiation of BMSCs under hypoxia induced by 
cobalt chloride 
A. Relative gene expression of endothelial cell markers in BMSCs cultured under 
different conditions; B. Flow cytometry graphs showing the expression of CD31 and 
VEGFR2 on BMSCs cultured under different conditions; C. Immunohistochemical 
staining (100×) of vWF and eNOSIII on HUVECs and BMSCs cultured under 
different conditions (a-c. vWF staining on BMSCs cultured in DMEM or DMEM plus 
100µM CoCl2 or both 20ng VEGF/ml and 100µM CoCl2; d. vWF staining on 
HUVECs; e-g. eNOSIII staining on BMSCs cultured in DMEM or DMEM plus 
100µM CoCl2 or both 20ng VEGF/ml and 100µM CoCl2; h. eNOSIII staining on 
HUVECs.)  
 
 
 
 
 
 92
 
Figure 6. Vessel-like structure formation on the Matrigel by HUVECs and 
BMSCs cultured under different conditions.  
a-d. vessel-like structures formed by BMSCs cultured in DMEM or DMEM plus 20, 
40 or 80ng/ml VEGF; e-f. vessel-like structures formed by BMSCs cultured in 
DMEM plus 100µM CoCl2 or both 20ng VEGF/ml and 100µM CoCl2; g. vessel-like 
structures formed by HUVECs; bar graph showing the number and statistical analysis 
of vessel-like structures formed by HUVECs and BMSCs cultured under different 
conditions. **: p<0.01 
 
The enhanced vessel formation of HUVECs on Matrigel by CoCl2-treated 
BMSCs 
HUVECs, when mixed with CoCl2-treated BMSCs in serum-free DMEM, formed 
more stable vessel-like strucutures after both 24hrs and 72hrs incubation on the 
Matrigel than HUVECs alone or with untreated BMSCs (one-way ANOVA, p<0.001) 
(Fig.7). The number of vessel-like structures formed by HUVECs- CoCl2-treated 
BMSCs mixture was more than other groups after both 24hrs and 72hrs incubation 
(one-way ANOVA, p<0.001) (Fig.7). 
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Figure 7. The enhanced vessel formation of HUVECs on Matrigel by 
CoCl2-treated BMSCs.  
A-D. vessel-like structures formed by HUVECs plus CoCl2-treated BMSCs or 
untreated BMSCs, CoCl2-treated BMSCs alone and HUVECs alone after 24hrs 
incubation in serum-free DMEM; E-H. vessel-like structures formed by HUVECs 
plus CoCl2-treated BMSCs or untreated BMSCs, CoCl2-treated BMSCs alone and 
HUVECs alone after 72hrs incubation in serum-free DMEM; I. bar graph showing the 
number and statistical analysis of vessel-like structures formed by different groups; In 
bar graph, BCH: HUVECs plus CoCl2-treated BMSCs; BH: HUVECs plus untreated 
BMSCs; C: CoCl2-treated BMSCs only; H: HUVECs only;***: p<0.001. 
 
In vivo vascularization ability of BMSCs cultured under different conditions 
After being retrieved from the SCID mice, the Matrigel implants were observed under 
a stereomicroscope and the images were taken (Fig.8 a-f). No obvious vascularization 
could be seen in the negative control, Matrigels carrying BMSCs or BMSCs treated 
with VEGF, while in the Matrigel carrying HUVECs, BMSCs treated with CoCl2 
alone or together with VEGF,  blood vessels could be seen (Fig.8 a-f). After Staining 
with the vWF antibody, positive cells and blood vessels on each slice were counted 
and normalized against the area of each slice. Results showed that Matrigels carrying 
HUVECs, BMSCs treated with  CoCl2  alone or together with VEGF had much 
more vWF+  cells and blood vessels than the negative control, Matrigels carrying 
BMSCs or BMSCs treated with VEGF (Friedman test, p<0.01) (Fig.8 g-p). Further 
VEGF and PEDF staining revealed that non-vascularized areas in Matrigels 
containing untreated BMSCs showed much stronger expression of PEDF compared to 
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the highly vascularized areas in Matrigels carrying CoCl2-treated BMSCs (Fig.9 A-D). 
On the other hand, in the Matrigel containing CoCl2-treated BMSCs, very strong 
VEGF expression was identified in both newly formed blood vessel wall and the 
surrounding cells (Fig. 9 E-H).   
 
 
Figure 8. In vivo vascularization ability of BMSCs cultured under different 
conditions 
a.Matrigel without pre-mixed cells; b. Matrigel with untreated BMSCs; c. Matrigel 
with BMSCs treated with 20ng/ml VEGF; d. Matrigel with BMSCs treated with 
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100µM CoCl2; e. Matrigel with BMSCs treated with both 100µM CoCl2 and 20ng/ml 
VEGF; f. Matrigel with HUVECs; g. vWF staining (100×) of Matrigel without cells; 
h. vWF staining (100×) of Matrigel with untreated BMSCs; i. vWF staining (100×) of 
Matrigel with BMSCs treated with 20ng/ml VEGF; j. vWF staining (100×) of 
Matrigel with BMSCs treated with 100µM CoCl2; k. vWF staining (100×) of Matrigel 
with BMSCs treated with both 100µM CoCl2 and 20ng/ml VEGF; l. vWF staining 
(100×) of Matrigel with HUVECs; m. Higher magnification (400×) of vWF staining 
of Matrigel with BMSCs treated with 100µM CoCl2 showing blood vessels and 
capillaries; n. Higher magnification (400×) of vWF staining of Matrigel with BMSCs 
treated with 100µM CoCl2, showing a small artery growing into the gel; o. Higher 
magnification (400×) of vWF staining of Matrigel with HUVECs, showing positive 
capillaries; p. Bar graphs showing the differences in vascularization among different 
matrigel groups (CON: Matrigel without cell; BM: Matrigel with untreated BMSCs; 
BV: Matrigel with BMSCs treated with 20ng/ml VEGF; BC: Matrigel with BMSCs 
treated with 100µM CoCl2; BVC: Matrigel with BMSCs treated with both 100µM 
CoCl2 and 20ng/ml VEGF; H: Matrigel with HUVECs.). **: p<0.01. 
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Figure 9. VEGF/PEDF expressions in Matrigels containing untreated or 
CoCl2-treated BMSCs. 
A. PEDF highly expressed in non-vascularized areas of Matrigel containing untreated 
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BMSCs (200×); B. A higher magnification (400×) of a local area in A (arrows 
indicating PEDF positive cells); C. Almost no PEDF expressed in highly-vascularized 
areas of Matrigel containing CoCl2-treated BMSCs (200×); D. A higher magnification 
(400×) of a local area in C; E. VEGF highly expressed on blood vessel walls and 
some surrounding cells (200×); F. Zoom-in image of the selected area in A (within red 
square frame) showing VEGF positive cells around the blood vessel; G&H. Higher 
magnification (400×) showing the VEGF (G) and vWF (H) expressions on two 
consecutive slices (arrows indicating VEGF positive cells).    
 
Discussion 
BMSCs are the cells isolated from the bone marrow mononuclear cells and attaching 
to the plastic cell culture surfaces. Whether those in vitro cultured BMSCs could be 
differentiated into endothial cells, or in the other word, whether in vitro cultured 
BMSCs contain EPCs, has long since been a controversy [170-171]. Multipotent adult 
progenitor cells (MAPCs), a recently identified elusive stem-cell population from 
bone marrow mononuclear cells, are reported to be able to differentiate into 
endodermal, mesodermal and ectodermal cells including endothelial cells[172].  To 
purify the MAPCs, fibronectine-coated cell culture surfaces and growth factors 
(platelet-derived growth factor-BB and Epidermal growth factor) are needed, which is 
different from that used for BMSCs isolation[172]. As MAPCs have not been well 
characterized against BMSCs and the modified purification method for MAPCs may 
be more favorable for different cell populations to attach, it is possible that MAPCs 
might be a mixture of BMSCs and HSCs. To simplify the question and investigate the 
endothelail cell differentiation ability of BMSCs, the traditional BMSCs isolation and 
expansion methods were used in this study, and only P2-P5 cells were included to 
make sure there is no HSCs contamination.  
BMSCs have been reported involved in various tissue development and regeneration 
processes, such as osteogenesis, chondrogenesis and angiogenesis[173-177]. In 
angiogenesis, what roles BMSCs are playing is not clear yet although some studies 
showed that BMSCs could support and help stabilize new-formed blood vessels as 
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pericytes [175-177]. In angiogenic environment, VEGF is a major pro-angiogenic 
growth factor that can help endothelial cell differentiation, migration and blood vessel 
formation [178-180], and its concentration is always increased in the angiogenic areas 
[181]. On the other hand, PEDF is the most potent natural angiogenesis inhibitor that 
can prevent vascularisation and induce the apoptosis of endothelial cells[167, 182]. 
The ratio or balance between these two antagonistic factors (VEGF/PEDF) in a local 
environment will affect the angiogenesis and vascularization in that area despite other 
pro- and anti-angiogenic factors[168]. Based on the findings in this study, the 
regulatory roles of BMSCs in neovascularization through adjusting VEGF/PEDF ratio 
could be illustrated in Fig.10. Although the VEGF expression of BMSCs has been 
investigated and reported [183-185], studies about the PEDF expression and the 
VEGF/PEDF expression pattern of BMSCs can hardly be found in literatures. The 
findings from this study reveal for the first time that PEDF is much more strongly 
expressed by BMSCs than the VEGF and other anti-angiogenic factors such as 
endostatin or chondromodulin (data not shown). Interestingly, HUVECs have much 
higher VEGF expression than the PEDF, which is exactly reverse to the BMSCs.  
These phenomena indicate that the BMSCs, when in a neutral environment, may not 
necessarily be an angiogenesis-promoting cell population. To be differentiated into 
endothelial cells, the VEGF/PEDF ratio of BMSCs should be reversed besides the 
expression of endothelial cell markers.   
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Figure 10. Illustration showing the regulatory role of MSCs in different 
situations. 
In pro-angiogenic environment, the extracellular VEGF concentration will be 
increased and varying during the angiogenic process[181]. No information could be 
found in literatures so far regarding alterations of the pro- and anti- angiogenic factor 
expression of BMSCs in pro-angiogenic environment with varying VEGF 
concentrations. In this study, the alterations of VEGF/PEDF expression under 
different extracellular VEGF concentrations were investigated. The findings showed 
that VEGF/PEDF expression ratio of BMSCs will increase as the extracellular VEGF 
concentration increases to 40ng/ml. If the extracellular VEGF concentration becomes 
more than 40ng/ml, the VEGF/PEDF ratio will fall back. These alterations in 
VEGF/PEDF expression pattern may indicate that when the environmental VEGF 
concentration is at an appropriate level, BMSCs will become more supportive in the 
angiogenic process; when there is too much VEGF in a local area, BMSCs may 
become less supportive. These findings may be useful in the application of BMSCs to 
help control angiogenesis or vascularization in vivo. As for the endothelial cell 
differentiation under various extracellular VEGF concentrations, BMSCs did not 
show any sign of differentiation towards endothelial cells, which means BMSCs 
cannot directly get involved in the blood vessel formation through the way of 
endothelial cell differentiation.  
Cobalt chloride is a hypoxia mimicking agent often used to activate hypoxia-related 
responses in cells[186]. The biochemical and molecule mechanisms of the hypoxia 
induced by CoCl2 are proven similar to that of the real hypoxia induced by low 
oxygen tension [186]. Although the gene expression alterations of BMSCs under the 
hypoxia condition have been reported [187], very few information could be found in 
literatures about the hypoxia effect on the VEGF/PEDF expression pattern of BMSCs. 
On the other hand, whether the endothelial cell differentiation ability of BMSCs will 
be improved under hypoxia conditions is still unknown. In this study, hypoxia induced 
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by CoCl2 increases the VEGF expression and suppresses the PEDF expression 
significantly, which means the hypoxia drives the BMSCs to favor angiogenesis and 
vascularisation. Unfortunately, no signs of differentiation towards endothelial cells 
were found in BMSCs cultured under hypoxia induced by CoCl2.  
To further investigate the role of BMSCs in angiogenesis, especially the BMSCs 
cultured in hypoxia conditions, the HUVECs were mixed with CoCl2-treated BMSCs 
or untreated BMSCs in serum-free media and seeded onto the Matrigel. CoCl2-treated 
BMSCs significantly enhanced and stabilized the vessel-like structure formation on 
the Matrigel. As the media is serum free, the upregulated VEGF expression in 
CoCl2-treated BMSCs could account for this phenomenon. For in vivo vascularization 
analysis, SCID mice were used and BMSCs cultured under various conditions were 
injected subcutaneously.  The implant with BMSCs treated with CoCl2 showed much 
higher degree of vasculariztion than the BMSCs cultured in nomoxia despite whether 
the extracellular VEGF was added or not, which could be attributed to the 
significantly increased VEGF/PEDF expression ratio in CoCl2-treated BMSCs. The 
VEGF/PEDF staining further revealed that VEGF/PEDF expression in a local area is 
closely linked with the neovascularization.  
Based on the findings in this study, it is reasonable to conclude that BMSCs involve in 
the angiogenesis as regulators rather than endothelial cell progenitors under both 
nomoxia and hypoxia conditions. BMSCs treated by hypoxia conditions can promote 
the vascularization in local areas and consequently be very useful in ischemia 
treatment and vascularized-tissue engineering.   
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Cobalt chloride-treated bone marrow mesenchymal stem cells (BMSCs) enhance 
in vivo osteogenesis of BMSCs-derived osteoblasts and vascularization in a tissue 
engineered periosteum model 
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Abstract 
The periosteum plays an indispensable role in both bone formation and defect healing.  
Developing a tissue engineered bi-layered periosteum may throw a new light on 
critical-sized bone defect restoration. This study constructed in vitro an artificial 
periosteum by incorporating BMSCs-derived osteoblasts alone or together with CoCl2 
pre-treated BMSCs or HUVECs, then the engineered periostea were implanted both 
subcutaneously (for two weeks) and into skull bone defects (for four weeks) of SCID 
mice to investigated ectopic and orthotopic osteogenesis and vascularisation. 
Micro-CT, histological and immunohistochemical methods were used to assess the 
ectopic and orthotopic osteogenesis and vascularisation after implants harvest. The 
results showed that CoCl2 pre-treated BMSCs and HUVECs induced a higher degree 
of vascularisation in implants (p<0.05). CoCl2 pre-treated BMSCs significantly 
enhanced the ectopic and orthotopic osteogenesis of BMSCs-derived osteoblasts 
(p<0.05), while HUVECs promoted orthotopic new bone formation after a four-week 
observation (p<0.05). No signs of new bone tissues but calcium precipitation were 
found in subcutaneously implanted scaffolds. Based on the findings of this 
experimental study, it could be concluded that CoCl2 pre-treated BMSCs can enhance 
both ectopic and orthotopic osteogenesis of BMSCs-derived osteoblasts and 
vascularization at an early osteogenic stage. Subcutaneous areas of mice may not be 
appropriate for assessment of new bone formation on collagen scaffolds. This study 
demonstrated the potential application of CoCl2 pre-treated BMSCs in tissue 
engineering not only for periosteum but also bone or other vascularized tissues.   
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Introduction 
Bone defects, especially large bone defects, remain a major challenge in orthopedic 
surgery [188]. Autologous bone transplantation is considered the most effective 
treatment, but insufficient donor tissue, coupled with concerns about donor site 
morbidity, has hindered this approach in large-scale applications.  On the other hand, 
immunological reactions that would occur in recipients against allo or xenogeneic 
bone grafts impose a major restriction on the clinical application of these approaches.  
In both physiological and pathological processes, the periosteum plays an 
indispensable role in both bone formation and defect healing alongside the 
involvement of various growth factors and mechanical loading [9, 20, 35].  
Periosteum is a dense, dual-layered and highly vascularized connective tissue 
membrane covering cortical bone surfaces [9, 14, 23].  The cambial layer of 
periosteum contains osteoblasts and osteogenic progenitor cells, whereas in the 
fibrous layer there are collagen fibers, fibroblasts and blood vessel networks.  It is 
the osteogenic function of periosteum that determines the rate of de novo postnatal 
periosteal bone formation and consequently the bone strength during the process of 
growth or defect healing [35].  Transplantation of autogenous or allogenous 
periosteum has been applied successfully in the restoration of various-sized bone 
defects, especially large bone defects [131, 189].  Bone healing induced by 
periosteum has several advantages compared to direct bone or bone substitute 
transplantation, such as healing with a natural bone structure, optimal bone integrity 
in the defect area, appropriate degree of vascularization, and minimal ectopic 
ossification through the defect encasement [131, 189].  However, major concerns in 
the case of autogenous periosteum transplantation include insufficient autologous 
donor tissues and donor site morbidity; and in the case of allogenous transplants, 
immunological rejection reactions.  
In vitro tissue-engineered periosteum, designed to mimic the anatomical structure of 
real periosteum, may provide a novel approach in the treatment of large bone defects.   
Bone marrow-derived mesenchymal stem cells (BMSCs) are a widely used progenitor 
cell source and are believed to be able to differentiate into osteogenic progenitor cells 
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and finally osteoblasts following ex vivo expansion under certain conditions. These 
osteoblasts are reportedly able to regenerate bone tissues lost in trauma or diseases by 
direct orthotopic placement in conjunction with appropriate scaffolds, most 
commonly those containing hydroxyapatite/tricalcium phosphate (HA/TCP)[190]. 
However, whether and how the in vitro differentiated BMSCs maintained the 
osteogenic phenotype on collagen scaffolds in vivo is still elusive although a lot of 
researches had used collagen as the cell carrier to restore bone defects[75]. On the 
other hand, as periosteum is a highly vascularized tissue, introducing new blood 
vessels into the engineered periosteum to form a dual-layered structure is essential for 
the function of engineered periosteum. Hypoxia will increase the expression of 
pro-angiogenic factors, such as VEGF, by BMSCs, and BMSCs pre-treated with 
hypoxia conditions can help restore the vascularization in ischemic tissues[191-192]. 
But on the other hand, whether these hypoxia-pre-treated BMSCs could enhance 
osteogenesis of BMSCs-derived osteoblasts as well as vascularisation needs further 
investigation.    
In this study, the concept of tissue engineered periosteum was investigated by 
combining BMSCs-derived osteoblast and endothelial cells or BMSCs pre-treated 
with cobalt chloride (CoCl2) -induced hypoxia on both sides of a collagen I membrane. 
The osteogenesis and vascularization of the tissue engineered periosteum were 
evaluated in both the subcutaneous area and skull defects of mice.   
 
Materials and methods 
Cells and cell cultures 
Bone marrow was obtained from hip and knee replacement patients in orthopedic 
department of the Prince Charles Hospital, Brisbane with informed consent and ethics 
approval from the Ethics Committee of Queensland University of Technology. 
Mononuclear cells (MNCs) were isolated from the bone marrow by density gradient 
centrifugation over Lymphoprep (Axis-shield PoC AS, Oslo, Norway) according to 
the manufacturer’s protocol. The MNCs were plated into the culture flasks and 
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cultured in Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen Pty Ltd., Mt 
Waverley, VIC, Australia) containing 10% (v/v) fetal calf serum (FCS; InVitro 
Technology, Noble Park, VIC, Australia) and 1% (v/v) penicillin/streptomycin 
(Invitrogen). The unattached hematopoietic cells were removed through media 
changes. When reaching the 70-80% confluence, the attached mesenchymal cells 
were subcultured using 0.25% trypsin (Invitrogen) with 1mM EDTA (Invitrogen). 
Only passages 2 to 5 (P2-P5) mesenchymal cells were used in this study. Human 
umbilical vein endothelial cells (HUVECs; Clonetics, San diego, CA, USA) were 
cultured in a defined endothelial cell growth medium containing VEGF, FGF-2, IGF-1, 
EGF, ascorbic acid and hydrocortisone (EGM-2; Lonza Australia Pty Ltd., Mt 
Waverley, VIC, Australia) supplemented with 2% FCS.  The medium was changed 
every three days until the cells were confluent.  
 
In vitro osteogenic differentiation and cobalt chloride treatment of BMSCs  
For the in vitro osteogenic differentiation, BMSCs were firstly seeded onto one side 
of collagen membrane and cultured in normal DMEM for 24hrs, then the DMEM was 
changed to osteogenic differentiation medium (10mM β-glycerophosphate, 50µM 
ascorbic acid and 100nM dexamethasone; Sigma Aldrich Pty Ltd, Castel Hill, NSW, 
Australia) 2 weeks prior to in vivo implantation. For the cobalt chloride-induced 
hypoxia treatment, BMSCs were firstly cultured in DMEM until reaching 70-80% 
confluence on cell culture flask surface, then the media was changed to the DMEM 
containing 10% (v/v) FCS and 100µM CoCl2 one week before the implantation.  
 
Periosteum tissue engineering 
Collagen membrane scaffolds were fashioned from a 1mm-thick bovine type I 
collagen sheet (Medtronic Australia Pty Ltd, North Ryde, NSW, Australia) using a 
hole puncher 5mm across and sterilized by soaking in 75% ethanol for 10mins, then 
washed at least three times in PBS prior to cell seeding.  The scaffold was fitted into 
a well of 96-well cell culture plate before 6 x 104 BMSCs were seeded on top of the 
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scaffolds and incubated in osteogenic differentiation media at 37oC and in 5% CO2 for 
2 weeks prior to implantation (Fig.2 A-F).  For the scaffolds carrying both 
osteogenesis-committed BMSCs and HUVECs or CoCl2 pre-treated BMSCs or untreated 
BMSCs, 1 x 105 HUVECs or CoCl2 pre-treated BMSCs or untreated BMSCs were 
seeded onto the other side of scaffolds 3hrs prior to implantation (Fig.2 A-F). For the 
scaffolds carrying only untreated BMSCs, 6 x 104 cells were seeded on top of the 
scaffold 2 weeks before the implantation. Scaffolds without cells were used as 
negative control.  
To find out cell seeding efficiency and ascertain cell attachment to the scaffolds, the 
cells that fell off the scaffold (n=3) were trypsinized and collected 3hrs after initial 
cell seeding or secondary cell seeding. Then the cell number was counted using a 
NucleoCounter (ChemoMetec A/S, DK-3450 Allerød, Denmark) and the seeding 
efficiency was calculated as the percentage of cells remaining on the scaffold to the 
total cells seeded.  To observe the cell attachment and distribution on scaffolds after 
initial cell seeding, the scaffold was fixed in 4% paraformaldehyde, embedded in 
paraffin and 5µm-thick serial sections were cut perpendicular to the cell seeding 
surface using a microtome (Leica Microsystems GmbH, Wetzlar, Germany). Cell 
nuclei were stained with DAPI (Molecular Probes, Invitrogen) and observed under a 
microscope (Carl Zeiss Microimaging GmbH, Gottingen, Germany) at 100 x 
magnification. To observe the cell attachment and distribution on scaffolds after 
secondary cell seeding, BMSCs labelled with intra-cellular green fluorescent 
nano-particles (Q-tracker 565; Invitrogen) were seeded onto the scaffolds carrying 
osteogenesis-committed BMSCs, and a 60m thick slice from cryosectioning was stained 
with DAPI and observed directly under a fluorescent microscope (Carl Zeiss 
Microimaging GmbH, Göttingen, Germany) at 100 x magnification.  
 
Subcutaneous implantation of tissue engineered periosteum in SCID mice  
Animal ethics approval for the use of severe combined immunodeficient (SCID) mice 
in this experiment was granted by the QUT Animal Ethics Committee. A total of four 
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5-week old male SCID mice (Animal Resources Centre, Canning Vale, WA, Australia) 
were used.  The animals were anesthetized with 1mL of ketamine (100mg/mL) and 
0.15 mL of xylazine (20mg/mL) injected intraperitoneally. Three small incisions were 
made longitudinally along the central line of the shaved dorsal area, approximately 
1cm apart, and subcutaneous pockets were made on each side of the incision with a 
pair of surgical scissors. Each individual pocket had in it one scaffold with different 
cell seeding strategy. Then the incisions were closed with surgical clips.  All animals 
recovered fully from the surgery by the following day and were sacrificed after two 
weeks. The implants were retrieved and pictures were taken using a digital camera. 
 
Skull defect implantation of tissue engineered periosteum in SCID mice  
A total of twenty-eight 5-week old male SCID mice (Animal Resources Centre, 
Canning Vale, WA, Australia) were used. The animals were anesthetized with 1mL of 
ketamine (100mg/mL) and 0.15 mL of xylazine (20mg/mL) injected intraperitoneally. 
One small incision was made longitudinally along the centre line of the shaved skull 
skin area (Fig.1 A). After the skull bone surface was exposed, the periosteum covering 
the bone surface was totally removed using a dental scraper (Fig.1 B). A Ø2.5mm 
defect was then made through the skull using a dental bur driven by a dental drilling 
machine (Fig.1 C-F). Care was taken during the drilling to avoid entering the dura. 
The phosphate buffered saline (PBS) was applied regularly onto the drilling site to 
prevent overheating-related damages to local tissues. The defect was then managed in 
the following seven different ways with four mice in each: i.e. empty defect, defect 
filled with collagen only or collagen plus BMSCs, Bost, Bost plus BMSCs or 
HUVECs or CoCl2 treated BMSCs. For the defect filled with scaffolds, one scaffold 
with different cell seeding strategy was gently inserted into the defect (Fig.1 G). Then 
the skin was replaced and the incision was closed with surgical clips (Fig.1 H). All 
animals recovered fully from the surgery by the following day and were sacrificed 
after four weeks. The skull defect area together with implants was harvested and 
pictures were taken by a digital camera. 
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Fig.1 Skull defect implantation of tissue engineered periosteum in SCID mice. (A. 
an incision made on the skull skin; B. periosteum was removed by a scraper; C. 
measurement of the dental bur diameter; D. drilling a hole defect on the skull; E. a 
defect made on the skull; F. measurement of the defect size; G. a defect filled with 
scaffold; H. incision closed with a clip.)   
 
Assessment of calcification by micro-CT scanning 
All implants were fixed in 4% paraformaldehyde solution overnight at room 
temperature and then washed in PBS. Cross-sectional scans parallel to the cell seeding 
surface of subcutaneous or skull defect implants were performed in a micro-CT 
scanner (CT40, SCANCO Medical AG, Brüttisellen, Switzerland) at a resolution of 
12m and three dimensional (3D) images of implants were reconstructed from the 
scans by the micro-CT system software package. To validate the in vivo calcification, 
scaffolds without cells or carrying untreated BMSCs or BMSCs-derived osteoblasts in 
vitro were fixed and scanned as well. For in vitro or subcutaneously implanted 
scaffolds, total volume and average density against hydro-apatite (HA) of calcification 
were measured and recorded by the micro-CT system software package for statistical 
analysis. For scaffolds in the skull defect, volume and average density against 
hydro-apatite (HA) of calcification within the defect area (defined by encircling the 
defect area on each micro-CT slice as area of interest) were measured and recorded 
for statistical analysis (Fig. 7 A-C).  
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Von Kossa staining for calcification in subcutaneous implants 
Following micro-CT scanning the subcutaneous implants were embedded in paraffin 
and 5µm-thick serial sections were cut perpendicular to the implants using a 
microtome (Leica Microsystems GmbH, Wetzlar, Germany). Slices near the central 
area of the implants were used for Von Kossa staining. In brief, after slice dewaxing 
and hydration, Mayer’s haematoxylin (HD Scientific Pty Ltd., Kings Park, NSW, 
Australia) were used for nuclear staining. 5% silver nitrate (Sigma-Aldrich) was 
added onto each slice and exposed to light for at least 30 minutes. Then the slices 
were briefly washed in distilled water and dehydrated in ethanol before being 
mounted with cover slides. The calcification was observed under a microscope (Carl 
Zeiss Microimaging GmbH, Göttingen, Germany) and images were taken. 
 
Assessment of new bone formation by histological H&E staining 
Following micro-CT scanning the skull defect implants were decalcified in 10% 
EDTA and embedded in paraffin as subcutaneous implants and 5µm-thick serial 
sections were cut perpendicular to the implants using a microtome (Leica 
Microsystems GmbH, Wetzlar, Germany).  Slices near the central area of the 
implants were used for the H&E staining. Briefly, following slice dewaxing and 
hydration, Mayer’s haematoxylin (HD Scientific Pty Ltd., Kings Park, NSW, 
Australia) was used for nuclear staining. After dehydration in alcohol with up-grading 
concentrations, cell plasma and extracellular matrix were stained by eosin (HD 
Scientific Pty Ltd., Kings Park, NSW, Australia). Based on H&E staining, de novo 
bone formation within the implants was observed and the area of new bone tissues on 
each slice was measured using AxioVision software (Carl Zeiss Microimaging GmbH, 
Göttingen, Germany). Three measurements from each implant were averaged and 
used for statistical analysis. 
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Assessment of vascularization and new bone formation using 
immunohistochemical staining   
Slices near the central area of the implants were used for the immunohistochemical 
staining.  A von Willebrand factor (vWF) antibody (mouse anti-human, Chemicom 
International Inc., Temecula, CA, USA) was used to identify the presence of 
endothelial cells in the implants. An alkaline phosphatase (ALP) antibody (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) was used to confirm newly formed bone in 
implants. In brief, following slice dewaxing and hydration, endogenous peroxidase 
activity was quenched by incubating the sample slices with 3% H2O2 for 20 minutes 
then blocked with 10% swine serum for 1 hour.  The samples were incubated with 
the vWF primary antibody (1:300) or ALP antibody (1:200) overnight at 4oC, 
followed by incubation, at room temperature, with a biotinylated swine-anti-mouse, 
rabbit, goat secondary antibody (DAKO Multilink, CA, USA) for 15 minutes, and 
then with horseradish perioxidase-conjugated avidin-biotin complex (DAKO 
Multilink, CA, USA) for another 15 minutes. The antibody complexes were 
visualized by the addition of a buffered diaminobenzidine (DAB) substrate for 4 
minutes.  Mayer’s haematoxylin (HD Scientific Pty Ltd., Kings Park, NSW, 
Australia) was used for counter staining. The number of vWF+ blood vessels were 
counted and normalized to the area of the implant on each slice.  Three 
measurements from each implant were averaged and used for statistical analysis.  
 
Double staining of both vWF and calcium on subcutaneous implants 
Double staining with vWF antibody and von Kossa method (calcium staining) was 
performed on subcutaneous implants to determine the distribution of and relationship 
between osteogenesis and vascularization.  In brief, following vWF staining, 5% 
silver nitrate (Sigma-Aldrich) was added onto each slice and exposed to light for at 
least 30 minutes and the slices briefly washed in distilled water and dehydrated in 
ethanol before being mounted with cover slides.   
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Statistical analysis 
Analysis was performed using SPSS software (SPSS Inc, Chicago, Il, USA). All the 
data were analyzed using one-way ANOVA or Friedman test for group differences. 
The significance level was set at p ≤ 0.05.   
 
Results 
In vitro Cell seeding efficiency and attachment in engineered periosteum 
As the bar graph in Fig.2 shows, the cell seeding efficiency was 92.3 ± 2.5% for the 
first cell seeding and 85.3 ± 5.0% for the second seeding. Paraffin slices stained by 
DAPI revealed that after initial cell seeding the cells attached to the collagen fibres 
and distributed evenly within the scaffold (Fig. 2G). Slices from cryosectioning 
revealed that most fluorescence-labelled BMSCs attached and distributed on the 
seeding side of scaffold (Fig. 2H).     
 
Fig.2 Cell seeding on collagen scaffolds. (A. illustration of a collagen membrane in 
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96-well plate; B. illustration of first cell seeding on one side of the collagen 
membrane; C. illustration of second cell seeding on the other side of the collagen 
membrane; D. actual image of a collagen membrane in 96-well plate; E. actual image 
of first cell seeding on one side of the collagen membrane; F. actual image of second 
cell seeding on the other side of the collagen membrane; G. paraffin slice stained with 
DAPI showing cell attachment and distribution on scaffolds after first seeding; H. 
Cryosectioned slice showing the distribution of secondarily seeded cells (with green 
fluorescence) on scaffolds.     
  
Osteogenesis in the subcutaneously implanted tissue engineered periosteum 
Upon general observation on the harvested implants, scaffolds carrying 
BMSCs-derived osteoblasts (Bost) alone or together with untreated BMSCs, 
HUVECs or CoCl2-treated BMSCs seemed denser and more opaque compared with 
scaffolds in vitro or seeded with no cells or with untreated BMSCs (Fig.3A-G).  
After micro-CT scanning and 3D reconstruction, total volume and average density  
of the calcified areas in different scaffolds were calculated automatically by the 
micro-CT software (Fig. 3H-N).  At the two week time point studied in this 
experiment, there was no calcification found in the naked scaffold or scaffold seeded 
with untreated BMSCs (Fig.2I-J); Very little calcification was identified in the 
scaffold carrying BMSCs and cultured in vitro in osteogenic media for two weeks 
(Fig.3H). Substantial amount of calcification was found in scaffolds seeded with Bost 
alone or together with untreated BMSCs,  HUVECs or CoCl2-treated BMSCs 
(Fig.3K-N), and the combination of Bost and CoCl2-treated BMSCs showed the 
highest volume of calcified areas (Fig.3, p<0.05, Friedman test). No significant 
differences were found in the average density of calcified areas among scaffolds 
seeded with Bost alone or together other cells (Fig.3, p>0.05, Friedman test). Upon 
H&E and Von Kossa staining on paraffin slices, no bone tissue formation was found 
in all different scaffolds (Fig.4 A-C & G-I), while calcium precipitation along 
collagen fibres (shown as black dots or areas on slices) was far more evident in 
subcutaneously implanted scaffolds carrying Bost alone or together with other cells 
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(Fig.3F & J-L) than the in vitro Bost-carrying scaffolds (Fig.4D). The slices from 
Bost plus CoCl2-treated BMSCs group showed more extensive calcification compared 
with other groups (Fig.4L).   
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Fig.3 In vitro scaffold, subcutaneous implants and Micro-CT scanning analysis. 
(A. in vitro Bost-carrying scaffold; B. harvested scaffold without seeding cells; C. 
harvested scaffold carrying BMSCs; D. harvested scaffold carrying Bost only; E. 
harvested scaffold carrying Bost plus BMSCs; F. harvested scaffold carrying Bost 
plus HUVECs; G. harvested scaffold carrying Bost plus CoCl2-treated BMSCs; H-N. 
3D reconstruction images corresponding to the scaffolds shown in A-G; Bost: 
BMSCs-derived osteoblasts; BOH: Bost plus HUVECs; BOC: Bost plus 
CoCl2-treated BMSCs; BOB: Bost plus BMSCs; BM: BMSCs only; COL: collagen 
scaffold only; Vitro: Bost-carrying scaffolds prior to implantation; *: p<0.05;***: 
p<0.001)     
 
Fig.4 H&E and von Kossa staining on in vitro and subcutaneous implants (100×). 
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(A. H&E staining on in vitro Bost-carrying scaffold; B. H&E staining on harvested 
scaffold carrying BMSCs only; C. H&E staining on harvested scaffold carrying Bost 
only; G. H&E staining on harvested scaffold carrying Bost plus BMSCs; H. H&E 
staining on harvested scaffold carrying Bost plus HUVECs; I. H&E staining on 
harvested scaffold carrying Bost plus CoCl2-treated BMSCs; D-F & J-L. von Kossa 
staining on the slices from the same groups as A-C & G-I.) 
 
Vascularisation in the subcutaneously implanted tissue engineered periosteum 
Upon general observation on the harvested implants,, scaffolds carrying both Bost and 
HUVECs or CoCl2-treated BMSCs seemed to have more blood vessels growing 
around and into the scaffold compared with other scaffolds (Fig.3F, G). 
Immunohistochemical staining against vWF showed that scaffolds carrying both Bost 
and HUVECs or CoCl2-treated BMSCs had more micro-blood vessels and higher 
degree of vascularisation than other scaffolds (Fig.5A-H, p<0.05, Friedman test). 
Although scaffolds seeded with Bost or plus untreated BMSCs had higher average of 
vessel density than the scaffolds without seeding cells or seeded with BMSCs only, 
the difference was not statistically significant (Fig.5, p>0.05, Friedman test). 
Calcium-vWF double staining revealed that vWF+ blood vessels distributed closely to 
the calcium precipitation areas (Fig.5 I). 
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Fig.5 Vascularisation in the subcutaneously implanted tissue engineered 
periosteum. (A. vWF+ blood vessels in harvested scaffold without seeding cells 
(200×); B. vWF+ blood vessels in harvested scaffold seeded with BMSCs only (200×); 
C. vWF+ blood vessels in harvested scaffold carrying Bost only (200×); D. vWF+ 
blood vessels in harvested scaffold carrying Bost plus BMSCs (200×); E. vWF+ blood 
vessels in harvested scaffold carrying Bost plus CoCl2-treated BMSCs (200×); F. 
vWF+ blood vessels in harvested scaffold carrying Bost plus HUVECs (200×); G&H. 
vWF+ blood vessels (arrows) in harvested scaffolds at higher magnification (400×); I. 
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Calcium-vWF double staining showing vWF+ blood vessels distributed closely to the 
calcium precipitation areas (400×); Bost: BMSCs-derived osteoblasts; BOH: Bost 
plus HUVECs; BOC: Bost plus CoCl2-treated BMSCs; BOB: Bost plus BMSCs; BM: 
BMSCs only; COL: collagen scaffold only; *: p<0.05 ) 
 
Osteogenesis in the skull-defect implanted tissue engineered periosteum 
Upon general observation of the harvested skull defect-implant complex, the defects 
without implants or filled with collagen sponge alone or plus BMSCs showed very 
limited repair compared with the defects filled with scaffolds carrying Bost or 
together with other cells (Fig.6 A-G). The collagen sponge without pre-seeded cells or 
with only BMSCs was almost degraded and absorbed in the defect area (Fig.6 B-C). 
After micro-CT scanning and 3D reconstruction, total volume and average density of 
the calcified areas within defects were calculated. The implants carrying Bost plus 
HUVECs or CoCl2-treated BMSCs showed significantly higher volume of calcified 
areas than other implants (Fig.7, p<0.001, one-way ANOVA test), while no significant 
difference was found in the average density among different groups (Fig.7, p>0.05, 
one-way ANOVA test). The top-bottom view of 3D reconstructed defect areas (Fig.7 
D-J) showed that the defects filled with implants carrying Bost plus HUVECs or 
CoCl2-treated BMSCs healed much better than other groups. H&E staining on slices 
revealed evident new bone formation within the implants carrying Bost alone or plus 
other cells (Fig.8 A-H), while very little bone formation was found in the defects 
without implants or filled with collagen sponge alone or plus BMSCs (Fig.8 A,D,G). 
The area of new bone tissues within implants on each slice was measured and the 
implants carrying Bost plus HUVECs or CoCl2-treated BMSCs had significantly more 
new bone tissues than other implants (Fig.8, p<0.001, one-way ANOVA test). The 
defects filled with these two kinds of implants were almost bridged by the newly 
formed bone tissues (Fig.8 E-H). Interestingly, the de novo bone tissue formed along 
and incorporated the collagen fibers into the newly formed bone (Fig.8 I-J). 
Immunohistochemical staining against alkaline phosphatase (ALP) further confirmed 
the newly formed bone tissue within implants was surrounded by ALP+ osteoblasts 
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(Fig.8 K).         
 
 
 
Fig.6 General observation on the harvested skull defect-implant complex. (A. 
defect without implant; B. defect filled with collagen only; C. defect filled with 
collagen plus BMSCs; D. defect filled with implant carrying Bost only; E. defect 
filled with implant carrying Bost plus BMSCs; F. defect filled with implant carrying 
Bost plus CoCl2-treated BMSCs; G. defect filled with implant carrying Bost plus 
HUVECs; H. Zoom in image of the selected area in G showing blood vessel ingrowth; 
I. Zoom in image of the selected area in F showing blood vessel ingrowth.) 
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Fig.7 Micro-CT scanning analysis on the harvested skull defect-implant complex. 
(A. encircling the implant on the CT slice where it just appears; B. encircling the 
implant on the CT slice when the scanning is through the centre of implant; C. 
encircling the implant on the CT slice where it just disappears; D. top-bottom view of 
the 3D reconstructed image of the defect without implant; E. top-bottom view of the 
3D reconstructed image of the defect filled with collagen only; F. top-bottom view of 
the 3D reconstructed image of the defect filled with collagen plus BMSCs; G. 
top-bottom view of the 3D reconstructed image of the defect filled with implants 
carrying Bost; H. top-bottom view of the 3D reconstructed image of the defect filled 
with implants carrying Bost plus BMSCs; I. top-bottom view of the 3D reconstructed 
image of the defect filled with implants carrying Bost plus CoCl2 treated BMSCs; J. 
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top-bottom view of the 3D reconstructed image of the defect filled with implants 
carrying Bost plus HUVECs; Bost: BMSCs-derived osteoblasts; BOH: Bost plus 
HUVECs; BOC: Bost plus CoCl2-treated BMSCs; BOB: Bost plus BMSCs; EMP: 
defect without implant; COLB: collagen plus BMSCs only; COL: collagen scaffold 
only; ***: p<0.001) 
 
Fig.8 H&E and ALP staining on the harvested skull defect-implant complex. (A. 
H&E staining on defect without implant (40×); B. H&E staining on defect filled with 
implant carrying Bost only (40×); C. H&E staining on defect filled with implant 
carrying Bost plus BMSCs(40×); D. H&E staining on defect filled with collagen only 
(40×); E. H&E staining on defect filled with implant carrying Bost plus HUVECs 
(40×); F. H&E staining on defect filled with implant carrying Bost plus CoCl2-treated 
BMSCs (40×); G. H&E staining on defect filled with collagen plus BMSCs (40×); H. 
A higher magnification showing the de novo bone formation in the defect area (100×); 
I & J. higher magnifications (200× and 400×) showing the de novo bone formed along 
and incorporated the collagen fibre; K. ALP staining showing ALP+ osteoblast 
surrounding the de novo bone tissue (400×); Bost: BMSCs-derived osteoblasts; BOH: 
Bost plus HUVECs; BOC: Bost plus CoCl2-treated BMSCs; BOB: Bost plus BMSCs; 
***: p<0.001) 
 
Vascularisation in the skull-defect implanted tissue engineered periosteum 
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Upon general observation on the harvested skull defect-implant complex, the defects 
filled with implants carrying Bost plus HUVECs or CoCl2-treated BMSCs showed 
more blood vessels growing into the defect area than other defects (Fig.5 F-I). 
Immunohistochemical staining against vWF revealed significantly more blood vessels 
and higher degree of vascularization in implants carrying Bost plus HUVECs or 
CoCl2-treated BMSCs than in other implants (Fig.9, p<0.001, one-way ANOVA test). 
vWF+ micro blood vessels were found gathering around the de novo bone tissues and 
penetrating into the newly formed bone tissues (Fig.9 G-L).  
 
Fig.9 Vascularisation in the skull-defect implanted tissue engineered periosteum. 
(A. vWF staining on harvested implant carrying Bost only (40×); B. vWF staining on 
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harvested implant carrying Bost plus BMSCs (40×); C. vWF staining on harvested 
implant carrying Bost plus CoCl2-treated BMSCs (40×); D. vWF staining on 
harvested implant carrying Bost plus HUVECs (40×); E-H. higher magnification 
(100×) of the vWF staining on harvested implants from the same groups as A-D; I-L. 
higher magnification (400×) of the vWF staining showing the vWF+ micro blood 
vessels gathering around and penetrating into the newly formed bone tissues; Arrows 
pointing to vWF+ micro blood vessels; Bost: BMSCs-derived osteoblasts; BOH: Bost 
plus HUVECs; BOC: Bost plus CoCl2-treated BMSCs; BOB: Bost plus BMSCs; ***: 
p<0.001)    
 
Discussion 
As recently pointed out in a review by Zhang et el, periosteum engineering could 
assist in structural de novo bone formation and is therefore a promising method for 
bone defect restoration [55].  Although much work has focused on the structure, cell 
populations and osteogenic mechanisms within the periosteum [18-19, 35, 59], few, if 
any, references were found which addresses engineered periosteum containing 
different cell populations such as osteogenic and pro-angiogenic cells, not to mention 
an in vivo assessment of any such constructs.  As far as we can ascertain, this is the 
first attempt to construct an artificial bi-layered periosteum with two different cell 
populations – osteogenic and pro-angiogenic cells – modeled on the natural structure 
of real periosteum.  Previous studies concerning artificial periosteum have described 
structures with a single cell population, and therefore differ considerably from the 
natural structure of real periosteum; the cell viability, stability, long-term function and 
clinical applicability of these artificial periostea are therefore questionable [56-58].  
For example, in one study a collagen sponge composite was seeded with only 
osteogenic cells in order to form a bio-artificial periosteum – vascularization was 
therefore not even considered [57].  Another study used an acellular periosteum 
replacement membrane to wrap the defect areas and could therefore not be considered 
as a tissue engineered periosteum [56].  In a third study submucosa from the small 
intestine was used to mimic periosteum onto which bone marrow stromal cells 
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(BMSCs) were seeded [58].  The obvious drawback of this latter approach is that 
scaffold materials have to be sourced from the small intestine necessitating the need 
for an operation to harvest donor materials.  In the experiment presented here, both 
osteogenic (BMSCs derived osteoblasts) and pro-angiogenic cells (endothelial cells or 
CoCl2-pre-treated BMSCs) were seeded onto either side of a collagen membrane, 
trying to reflect the basic cellular and structural features of real periosteum.   
Although there are many other cell populations residing within the real periosteum, 
osteogenic and endothelial cells are the major and most important populations [11] 
and the interactions between the osteogenesis and vascularisation determine the 
osteogenic function of periosteum to a large extent. To enhance the vascularisation of 
an engineered tissue or organ, there are many different methods and three of them are 
most often used: i) add autogenous or allogenous endothelial cells which could be 
directly incorporated into the host blood vessel networks[6, 74]; ii) impregnate 
pro-angiogenic growth factors, such as VEGF, bFGF, PDGF ect., into the scaffold to 
incur the new blood vessel ingrowth[8, 119]; iii) incorporate gene vectors (plasmid or 
virus) encoding pro-angiogenic growth factors or cells transfected by those gene 
vectors with scaffolds to attract new blood vessels[185]. Unfortunately, the drawbacks 
of these methods are as evident as their believed advantages, such as immunological 
reactions when using allogenous endothelial cells, the low in vitro growth rate of 
autologous endothelial cells, biological safety concerns about the gene vectors or 
transfected cells and unstable temporal and spatial release of pro-angiogenic growth 
factors in defect areas. Some studies had tried to induce autologous bone 
marrow-derived mesenchymal stem cells to differentiate towards endothelial cells, but 
the results so far are still elusive and uncertain[170-171]. On the other hand, it has 
been reported that either low oxygen pressure or hypoxia-mimicing agents, such as 
CoCl2 or hydrogen peroxide (H2O2), can upregulate the expression of pro-angiogenic 
growth factors, VEGF in particular, in a variety of cells including BMSCs[187, 193]. 
The hypoxia pre-treated BMSCs had been successfully used to help re-vascularize the 
ischemic or infarcted muscles in animal models[191-192]. In this experimental study, 
BMSCs were pre-treated with the hypoxia-mimicing agent CoCl2 and the VEGF 
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expression after treatment was found to be increased by around 5 fold in our previous 
studies. As VEGF is an important growth factor which has been reported closely 
involved in both angiogenic and osteogenic processes [152, 163-164], the CoCl2 
pre-treated BMSCs were incorporated together with BMSCs-derived osteoblasts into 
the engineered periosteum model to see whether they could enhance both 
osteogenesis and vascularization in vivo.  
Two different animal models are often used to assess the in vivo osteogenic ability of 
engineered tissues: subcutaneous (ectopic) and bone defect (orthotopic) osteogenesis 
models. In this study, both models were included. During pathological and normal 
physiological osteogenesis, two distinct patterns of bone formation are involved – 
intramembranous and endochondral ossification.  Intramembranous ossification 
predominantly takes place in the periosteum during normal bone formation in which 
osteoprogenitor cells differentiate directly into osteoblasts laying down new bone 
tissues [194].  Although much has been reported about both in vivo and in vitro 
interactions between osteogenesis and vascularization [6, 8], the knowledge of in vivo 
interactions between osteogenesis and vascularisation, especially those during early 
osteogenic stages and related to periosteal intramembranous ossification, is still very 
much patchy.  Early stage histological and ultrastructural changes in microvessels of 
periosteal calluses after bone facture, using the light and electron microscope, has 
been described previously, but no quantitative data about the interaction between 
osteogenesis and vascularization was provided [49].  In the present study, 
observations and assessments about the osteogenesis and vascularisation at a 
relatively early stage in the engineered periosteum were performed two weeks after 
subcutaneous implantation and four weeks after skull defect implantation.  
Osteogenesis and vascularization were then quantified using micro-CT scanning, 
histological and immunohistochemical methods [195].  Our findings showed that 
subcutaneously implanted scaffolds presented no signs of new bone formation despite 
more extensive calcification compared with scaffolds prior to in vivo implantation, 
while in skull defects de novo bone tissues were evident. Although the observation 
time for subcutaneously and skull defect implanted scaffolds was different, no signs 
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of new bone tissues in the subcutaneously implanted scaffolds might still indicate that 
the differences in micro-environment at different implantation sites may determine 
different pattern of osteogenesis. Another noteworthy point is that in the skull defect 
naked collagen implants or implants carrying only BMSCs were almost bio-degraded 
and generated very limited new bone tissue within the defect when compared with 
implants carrying BMSCs-derived osteoblasts (Fig.8 A,D,G). This phenomenon 
suggests that new bone formation may require the orchestration of an 
osteogenesis-favouring environment, appropriate calcium precipitation on the 
collagen fibres and osteogenic cells.   
As for the vascularisation, HUVECs and CoCl2 pre-treated BMSCs helped increase 
blood vessel density in both subcutaneously and skull defect implanted scaffolds 
compared with others without these two kinds of cells. Interestingly, the addition of 
HUVECs only enhanced the osteogenesis in skull defect-filling implants but not in 
subcutaneously implanted scaffolds. It is different from CoCl2 pre-treated BMSCs 
which enhanced the osteogenesis in both situations. This difference could be 
accounted for in terms of the mechanisms these two different cells exploit to enhance 
osteogenesis. The upregulated VEGF expression by CoCl2 pre-treated BMSCs could 
start to stimulate the osteogenesis of BMSCs-derived osteoblasts as soon as the cells 
are seeded and this osteogenic process could be even more enhanced by subsequently 
enhanced vascularization. Alternatively, HUVECs might promote osteogenesis only 
after the supportive role of enhanced vascularization occurs as the natural VEGF 
expression of HUVECs was found to be quite low according to our previous studies. 
The calcium-vWF double staining and vWF+ micro blood vessels surrounding de 
novo bone tissues also revealed the close relationship between osteogenesis and 
vascularization. To confirm the pro-osteogenic and angiogenic effects of CoCl2 
pre-treated BMSCs, untreated BMSCs were used together with BMSCs-derived 
osteoblasts as an internal control. The findings in this study showed that the addition 
of untreated BMSCs would not significantly help the in vivo ectopic or orthotopic 
osteogenesis by BMSCs-derived osteoblasts and vascularization. The roles of 
undifferentiated BMSCs in osteogenic environments need further investigation.          
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Based on the findings of this experimental study, it could be concluded that CoCl2 
pre-treated BMSCs can enhance both ectopic and orthotopic osteogenesis of 
BMSCs-derived osteoblasts and vascularization at an early osteogenic stage, while 
endothelial cells can promote osteogenesis only after four-weeks. Subcutaneous areas 
of mice may not be appropriate for assessment of new bone formation on collagen 
scaffolds. This study demonstrated the potential application of CoCl2 pre-treated 
BMSCs in the tissue engineering not only for periosteum but also bone or other 
vascularized tissues.   
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CHAPTER 5 SUMMARY AND DISCUSSION 
Many Bone substitute materials have been developed in recent years. However, blood 
supply in large bone defects is still one of the unsolved major challenges after these 
bone substitute materials are filled into defect areas.  Periosteum plays an important 
and indispensable role in forming vascularized bone not only in bone development but 
also in bone defect healing. The initial rationale for this project was to construct a 
functional in vitro periosteum and then test its ability to aid the repair of critical-sized 
bone defect in animal models. In spite of the many efforts by other researchers, the 
actual construction of a functional and highly vascularized periosteum using 
autologous single stem cell source is still a considerable challenge. In an effort to 
construct a bio-mimetic tissue engineered periosteum, this project was designed with 
three separate but closely-linked experiments, which in the end led to four 
independent papers summarized in this thesis. The thought behind the design was that 
before commencing the periosteum engineering, it was important to better understand 
the structures and cell populations in the physiological periosteum, as well as the 
changes of periosteum in active stage of osteogenesis and physiological conditions 
such as ageing and oeteoporosis. Subsequently, a dual layered periosteum was 
constructed to induce or enhance the vascularization. Since the blood supply is one of 
the major part in the process of de novo bone formation in vivo, this project 
investigated the regulatory role of BMSCs in blood vessel formation. BMSCs are 
considered to play the primary role in inducing both osteogenesis and vascularization 
in the engineered periosteum since BMSCs are a source rich in stem cells and easy to 
obtain in terms of future clinical applications. To achieve this purpose, the focus was 
set upon the endothelial cell differentiation potential of BMSCs or the use of BMSCs 
to regulate vascularization as the osteogenic differentiation of BMSCs has been well 
established.  The tissue engineered periosteum was further evaluated by the in vivo 
tissue formation after implantation of the construct into SCID mice subcutaneously 
and into a skull bone defect model.    
 
To construct the periosteum which is mimicking the physiological periosteum not 
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only anatomically but also functionally and applicable in vivo, the structure and cell 
populations in physiological periosteum have been firstly investigated in depth and 
formed the basis of knowledge for the tissue engineered periosteum construction. 
Although the general structural and cell populations in periosteum have been well 
studied and established, the specific information about the site- and age-related 
alterations in periosteum anatomy and physiology is still lacking. On the other hand, 
whether the bone health status has the influence on the periosteum and its function is 
not known either. To answer these questions, the periostea on both diaphyseal and 
metaphyseal bone surfaces of femurs from rats of different ages or with induced 
osteoporosis were observed. Our findings revealed for the first time that despite the 
diaphyseal periosteum showed age-related degeneration which is indicated by the 
decrease in both the thickness and cell number in the periosteum, the metaphyseal 
periosteum from aged rats became thicker, more cellular but also more destructive as 
more osteoclasts were identified within the periosteum. Macrophages in the 
periosteum, as were found to be high in cell density in both young and aged rats,  
may in effect have a dual, age dependent role in bone metabolism: in young rats that 
of osteogenesis, and in aged rats that of osteoclastogenesis. The periosteum from 
osteoporotic bones differs from normal bones both in terms of structure and cell 
populations. This is especially evident in the cambial layer of metaphyseal periosteum.  
Bone resorption appears to be more active in the periosteum from osteoporotic bones, 
whereas bone formation activity is comparable between the osteoporotic and normal 
bone. The dysregulation of bone resorption and formation in the periosteum, 
characteristic of the pathogenesis of osteoporosis, may also be the effect of the 
interaction between various neural pathways and the cell populations residing within 
it. All these findings are indicating that the structure and cell population in periosteum 
are closely linked with bone metabolism and health status which are varying with age 
and different between bones or bone portions. Young and fast growing bone or bone 
portions with normal calcium metabolism would have thicker and more osteogenic 
periosteum, while periostea from elder or osteoporotic patients, especially those from 
the metaphyseal area of long bone, would be less osteogenic or even bone resorptive. 
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This phenomenon is of significance in guiding clinical periosteum transplantation as 
well as the periosteum engineering. Despite the findings from this project, further 
investigations about the structure and cell populations on different bones, especially 
weight-bearing and non-bearing bones, should be performed to help understand how 
mechanical stresses affect the structure and cell populations in periosteum.   
 
As revealed in the investigation on periosteum anatomy, the active osteogenesis in 
periosteum requires higher degree of vascularization. To achieve both osteogenesis 
and vascularization in the constructed periosteum, different cell sources have been 
used, such as osteoblasts and endothelial cells. In this PhD project, the novel concept 
of using a single adult stem cell source (BMSCs) to achieve both osteogenesis and 
vascularization in the constructed periosteum was tested. As the osteogenic 
differentiation ability of BMSCs has been well proved, the focus of this project was 
set upon the endothelial cell differentiation of BMSCs and how to use BMSCs to 
induce higher degree of in vivo vascularization. The endothelial cell differentiation of 
BMSCs has long since an unsettled controversy and a lot of conflicting reports can 
often be found in published literatures. This project provided a complete investigation 
on both endothelial cell differentiation and pro-/anti-angiogenic factor expression of 
BMSCs under both normoxia and hypoxia conditions. Our findings revealed that 
BMSCs most likely cannot be differentiated into endothelial cells through the 
application of pro-angiogenic growth factors or by culturing under hypoxic conditions. 
However, they may involve in angiogenesis as regulators under both nomoxic and 
hypoxic conditions. Two major angiogenesis-related growth factors, VEGF 
(pro-angiogenic) and PEDF (anti-angiogenic) were found to have altered expression 
in accordance with the extracellular environment. BMSCs treated with the 
hypoxia-mimicking agent CoCl2 expressed more VEGF and less PEDF and enhanced 
the vascularization of subcutaneous implants in vivo. These findings tried for the first 
time to settle the controversy about the physiological role of mesenchymal stem cells 
in angiogenesis and vascularization, and confirmed that BMSCs are important 
regulators rather than endothelial cell progenitors in the angiogenic process. BMSCs 
 130
regulate the angiogenic process through adjusting the expression of pro- and 
anti-angiogenic factors in different extracellular micro-environments. These findings 
throw a new light on the application of BMSCs in controlling angiogenesis in vivo 
and constructing vascularized tissues. The molecular mechanism lying behind the 
regulatory role of BMSCs in different extracellular micro-environments needs to be 
further investigated. For example, how does the extracellular VEGF affect the 
VEGF/PEDF expression of BMSCs? Is there any specific cell surface receptor or 
intracellular signal pathway involved in the regulatory role of BMSCs in 
vascularization? The hypoxia was induced by CoCl2 in this project, and the effect of 
real hypoxia induced by low oxygen partial pressure on BMSCs should be 
investigated in the future as well as underlying molecular mechanisms.    
 
Since the hypoxia can boost the VEGF expression in BMSCs and VEGF is a coupling 
factor between the osteogenesis and vascularization, it should be of great significance 
to use hypoxia pre-treated BMSCs to induce or enhance both osteogenesis and 
vascularization in engineered periosteum. CoCl2 is a proven hypoxia mimicking 
reagent as well as a FDA approved medicine for the anemia treatment, and can 
significantly increase the VEGF expression of BMSCs as confirmed in this project. 
Using CoCl2 to increase the VEGF expression of BMSCs is much easier and simpler 
than the real hypoxia which normally needs special incubator or chamber with 
lowered oxygen partial pressure. Although there had been reports testing the ability of 
hypoxia pre-treated MSCs to help revascularize ischemic tissues in vivo, very few 
trials, if any, can be found in literatures about the application of hypoxia pre-treated 
BMSCs in engineering vascularized tissues, such as bone and periosteum. The 
findings of this study revealed in the animal model that BMSCs pre-treated with 
CoCl2 could enhance both ectopic and orthotopic osteogenesis of BMSCs-derived 
osteoblasts and vascularization at the early osteogenic stage, and that endothelial cells 
were only capable of promoting osteogenesis after an extended period of four-weeks. 
The interaction between the endothelial cells and osteogenic cells should be further 
investigated in the future. On the other hand, the subcutaneous area of the mouse is 
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most likely inappropriate for assessing new bone formation on collagen scaffolds as 
no new bone formation was observed in the subcutaneous area. The local 
microenvironment seems playing significant roles in determining the mineralization 
pattern of transplanted BMSCs: clacification or new bone formation. Besides, 
although these findings revealed the close relationship between the vascularization 
and osteogenesis at an early osteogenic stage, how the vascularization and 
osteogenesis interact with each other at later osteogenic stages would be of great 
interest and should also be investigated. This study demonstrated the potential 
application of CoCl2 pre-treated BMSCs in the tissue engineering not only for 
periosteum but also bone or other vascularized tissues. Whether the real 
hypoxia-treated BMSCs could play a similar role is a question as well that needs to be 
answered in my future studies. 
 
In summary, periosteum is actually a highly complex organ containing different cell 
populations, extracellular matrix and bioactive molecules. In this PhD project, I have 
investigated the cellular structure of physiological periosteum and focused on 
potential cell application in vascularization. The tissue engineered periosteum is in 
many ways comparable to the actual physical periosteum, in both structural and 
functional aspects, however it is not a trivial undertaking and much future effort is 
still required to create a synthetic periosteum that truly mimics the function of 
physiological periosteum.  
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